

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

ID AE001587 standard; DNA; PRO; 16448 BP.
 XX
 AC AE001587; AE001363;
 XX
 SV AE001587.1
 XX
 DT 15-MAR-1999 (Rel. 59, Created)
 DT 02-SEP-2002 (Rel. 72, Last updated, Version 5)
 XX
 DE Chlamydia pneumoniae section 3 of 103 of the complete genome.
 XX
 KW .
 XX
 OS Chlamydophila pneumoniae CWL029
 OC Bacteria; Chlamydiae; Chlamydiales; Chlamydiaceae; Chlamydophila;
 OC Chlamydophila pneumoniae.
 XX
 RN [1]
 RP 1-16448
 RX MEDLINE; 99206606.
 RX PUBMED; 10192388.
 RA Kalman S., Mitchell W., Marathe R., Lammel C., Fan J., Hyman R.W.,
 RA Olinger L., Grimwood J., Davis R.W., Stephens R.S.;
 RT "Comparative genomes of Chlamydia pneumoniae and C. trachomatis";
 RL Nat. Genet. 21(4):385-389(1999).
 XX
 RN [2]
 RP 1-16448
 RA Kalman S., Mitchell W., Marathe R., Lammel C., Fan J., Olinger L.,
 RA Grimwood J., Davis R.W., Stephens R.S.;
 RT ;
 RL Submitted (01-DEC-1998) to the RL Program in Infectious Diseases, University o
 RL Hall, Berkeley, CA 94720, USA
 XX
 DR SPTREMBL; Q9Z9F7; Q9Z9F7.
 DR SPTREMBL; Q9Z9F8; Q9Z9F8.
 DR SPTREMBL; Q9Z9G0; Q9Z9G0.
 DR SPTREMBL; Q9Z9G1; Q9Z9G1.
 DR SWISS-PROT; Q9Z9F9; Y022_CHLPN.
 XX
 FH Key Location/Qualifiers
 FH
 FT source 1..16448
 FT /db_xref="taxon:115713"
 FT /organism="Chlamydophila pneumoniae CWL029"
 FT /strain="CWL029"
 FT misc_feature 172..2957
 FT /note="Polymorphic Outer Membrane Protein G Family;
 FT contains frame shift"
 FT misc_feature 3196..5953
 FT /note="Polymorphic Outer Membrane Protein G Family;
 FT contains frame shift"
 FT misc_feature 6302..9139
 FT /note="Polymorphic Outer Membrane Protein G Family;
 FT contains frame shift"
 FT CDS complement(9380..11467)
 FT /codon_start=1
 FT /db_xref="SPTREMBL:Q9Z9G1"
 FT /transl_table=11
 FT /gene="CPn0020"

```

FT      /product="Predicted OMP [leader peptide: outer membrane]"
FT      /protein_id="AAD18173.1"
FT      /translation="MKRCFLFLASFVLMGSSADALTHQEAVKKKNSYLSHFKSVSGIVT
FT      IEDGVLNIHNNLRIQANKVYVENTVGQSLKLVAHGNVMVNYRAKTLVCDYLEYYEDTDS
FT      CLLTNGRFAMYPWFLGGSMITLTPETIVIRKGYISTSEGPKKDLCLSGDYLEYSSDSL
FT      SIGKTTLRVCRIPIFLFPFIMPMEIPKPPINFRGGTGGFLGSYLGMSYSPISRKHFS
FT      STFFLDSFFKHGVMGFNLHCSQKQVPENVMKSYAHRLAIDMAEAHRYRLHGDFC
FT      FTHKHVNFSGEYHLSDSWETVADIFPNNFMLKNTGPTRVDCWTDNDYFEGYLTSSVKVN
FT      SFQANQELPYLTLRQYPISIIYNTGVYLENIVECGYLNFAFSDHIVGENFSSLRLAARP
FT      KLHKTVPPLPIGTLSSSLGSSLIYYSDVPEISSRHSQLSAKQLDYRFLHKSIIQRRHI
FT      IEPFVTFITETRLAKNEDHYIFSIQDAFHSLNLLKAGIDTSVLSKTNPRFPRIHAKLW
FT      TTHILSNTESKPTFPKTACELSLPFGKNTVSLDAEWIWKHCWDHNMNIRWEWIGNDNV
FT      AMTLESLHRSKSYSLIKCDRENFI LDVSRPIDQLLDSPLSDHRNLI L GKLFVRPHPCWNY
FT      RLSLRYGWHRQDTPNYLEYQMILGTKEFEHWQLYGVYERREADSRFFFFLKLDPKPKPP
FT      F"
FT      CDS      complement(11484..13190)
FT      /codon_start=1
FT      /db_xref="SPTREMBL:Q9Z9G0"
FT      /transl_table=11
FT      /gene="CPn0021"
FT      /product="Predicted OMP [leader peptide]"
FT      /protein_id="AAD18174.1"
FT      /translation="MGLFHLTLFGLLLCSLPISLVAKFPESVGHKILYISTQSTQQALA
FT      TYLEALDAYGDHDFVLRKIGEDYLYKQSIHSSDPQTRKSTIIAGLAGSSEALDVLSQLA
FT      METADPLQQLLVLSAVSGHLGKTSDDLFLKALASPYPVIRLEAAYRLANLKNKTKVIDHL
FT      HSFIHKLPEEIQCLSAAILRLETEESDAYIRDLLAAKKSARSATALQIGEYQQKRFL
FT      PTLRNLLTSASPQDQEAIIYALGKLKDGQSYNIKKQLQKPDVDVTLAAAQALIALGKE
FT      EDALPVIKKQALEERPRALYALRHLPEIGIPIALPIFLKTKNSEAKLNVALALLELGC
FT      DTPKLLEYITERLVQPHYNETLALSFSKGRTLQNWKRVIIVPQDPQERERLLSTTRGL
FT      EEQILTFLFRLPKEAYLPCIYKLLASQKTQLATTASFLSHTSHQEALDLLFQAALPG
FT      EPIIRAYADLAIYNLTKDPEKKRSLHDYAKKLIQETLLFVDTENQRPHPSPMYLRYQVT
FT      PESRTKLMLDILETLATSKSSEDIRLLIQLMTEGDAKNFPVLAGLLIKIVE"
FT      CDS      complement(13172..13762)
FT      /codon_start=1
FT      /db_xref="SWISS-PROT:Q9Z9F9"
FT      /transl_table=11
FT      /gene="maf"
FT      /product="Maf-type protein"
FT      /protein_id="AAD18175.1"
FT      /translation="MSLPLVLGSSSPRRKFILEKFRVPFTVI PSNFDESKVSYSGDPIA
FT      YTQELAAQKAYAVSELHSPDCIILTGDITVSYDGRIFTKPKQKADAIQMLKTLRNQTH
FT      DVVTSIAVLHKGKLLTGSETSQISLTMIPDHRIESYIDTVGTLNNGCAYDVCHGGLILK
FT      KVHGCYVNVQGLPIQTLKYLLEELNIDLWDYSI"
FT      CDS      complement(13791..15383)
FT      /codon_start=1
FT      /db_xref="SPTREMBL:Q9Z9F8"
FT      /transl_table=11
FT      /gene="yjjK"
FT      /product="ABC Transporter Protein ATPase"
FT      /protein_id="AAD18176.1"
FT      /translation="MSIVLDKIGKSLGTRILFDDVSFVFNPGNCYGLTGPNAGAKSTLL
FT      KIIMGIEPTRGSISLPKKVGILRQNIDSFHDTTVLDCVIMGNTRLWEALQRRDNLYLQ
FT      EFTDAIGMELGEIEEIIIGEENGYRADSEAEELLTGIGIPNEMFDKKMAMIPIDLQFRVL
FT      LCQALFGHPEALLLDEPTNHLDLYSINWLGNFLKDYEGTVIVVSHDRHFLNTITTHIAD
FT      IDYDTIIIIYPGNYDDMVEMKTASREQEKAIDKSKEKKISQLKEFVAKFGAGSRASQVQS
FT      RLREIKKLQPELKKSNIRPYIRFPLSDKSSGKVLSLEAITKDYGDHGVHPFSLEI
FT      YQGDKLGIIGNNGLGKTTLMKLLAGVEAPSSGSIKLGHQAI CSYFPQNHSDVLADCGQE
FT      TLFEWLRNRKTGINDQEIRSVLGKMLFGGDDAFKQIQALSGGETARLLMAGMMLNHNH
FT      LI LDEANNHLDESVSALSWAINDYKGTAFVSHDRGLIQDCATKLLIFDKDKITFFDG
FT      TMVDYTAGHKQLL"

```

FT CDS complement(15438..16376)
 FT /codon_start=1
 FT /db_xref="SPTREMBL:Q9Z9F7"
 FT /transl_table=11
 FT /gene="xerC"
 FT /product="Integrase/recombinase"
 FT /protein_id="AAD18177.1"
 FT /translation="MIAISIYSFLDYLMVKSPHTLRNYCLDLNGLKIFLEERGNLAP
 FT SSPLQLATEKRKVSELPFSLFTKEHVRMYIAKLIENGKAKRTIKRCLSSIKSFAHYCVI
 FT QKILLENPAETIHGPRLPKELPSPMTYAQVEVLMATPDISKYHGLRDRCLMELFYSSGL
 FT RISEIVAVNKQDFDLSTHLIRIRGKGKKERII PVTSNAIQWIIQIYLNHPDRKRLEKDPQ
 FT AIFLNRFGRRISTRSIDRSFQEYLRSSGLSGHITPHTIRHTIATHWLESMDLTKTIQAL
 FT LGHSSLETTTVYTQVSVKLKKQTHQEAPHAPH"

XX

SQ Sequence 16448 BP; 4710 A; 3330 C; 3665 G; 4743 T; 0 other;

tgatccctca	aaatcacatt	ttggtatctg	attgctaaga	ttgcaggata	ccacgcatct	60
taagagaaag	gcgctcttac	ctagtagagg	ttgagtgaat	ttcttgactt	gtttctccta	120
ttggtgtatc	tcttaaaata	ttaaattcaa	aatcaaagta	tatatctttac	aatgaagtct	180
tctttcccca	agtttgtatt	ttctacattt	gctattttcc	ctttgtctat	gattgctacc	240
gagacagttt	tggattcaag	tgcgagtttc	gatgggaata	aaaatggtaa	tttttcagtt	300
cgtgagagtc	aggaagatgc	tggaactacc	tacctattta	agggaaatgt	cactctagaa	360
aatattcctg	gaacaggcac	agcaatcaca	aaaagctggt	ttaacaacac	taagggcgat	420
ttgactttca	caggtaacgg	gaactctcta	ttgttcctaaa	cggtggatgc	agggactgta	480
gcaggggctg	ctgttaacag	cagcgtggta	gataaatcta	ccacgtttat	agggttttct	540
tcgctatctt	ttattgcgtc	tcctggaagt	tcgataacta	ccggcaaagg	agccgttagc	600
tgctctacgg	gtagcttgag	tttgacaaaa	atgtcagttt	gctcttcagc	aaaaactttt	660
caacggataa	tggcgggtgct	atcaccgcaa	aaactctttc	attaacaggg	actacaatgt	720
cagctctgtt	ttctgaaaat	acctcctcaa	agaaaggcgg	agccattcag	acttccgatg	780
cccttaccat	tactggaaac	caaggggaag	tctctttttc	tgacaatact	tcttcggatt	840
ctggagctgc	aattttttaca	gaagcctcgg	tgactatttc	taataatgct	aaagtttctt	900
ttattgacaa	taaggtcaca	ggagcgaagt	cctcaacaac	gggggatatg	tcaggagggtg	960
ctatctgtgc	ttataaaaact	agtagagata	ctaaggctcac	cctcactgga	aatcagatgt	1020
tactcttcag	caacaataca	tcgacaacag	cgggaggagc	tatctatgtg	aaaaagctcg	1080
aactggcttc	cggaggactt	accctattca	gtagaaatag	tgtcaatgga	ggtacagctc	1140
ctaaagggtg	agccatagct	atcgaagata	gtggggaatt	gagtttatcc	gccgatagtg	1200
gtgacattgt	cttttttaggg	aatacagtca	cttctactac	tcctgggacg	aatagaagta	1260
gtatcgactt	aggaacgagt	gcaaagatga	cagctttgcg	ttctgctgct	ggtagagcca	1320
tctacttcta	tgatcccata	actacaggat	catccacaac	agttacagat	gtcttaaaag	1380
ttaatgagac	tccggcagat	tctgcactac	aatatacagg	gaacatcatc	ttcacaggag	1440
aaaagttatc	agagacagag	gccgcagatt	ctaaaaatct	tacttcgaag	ctactacagc	1500
ctgtaactct	ttcaggagggt	actctatctt	taaaacatgg	agtgactctg	cagactcagg	1560
cattcactca	acaggcagat	tctcgtctcg	aaatggacgt	aggaactact	ctagaacctg	1620
ctgatactag	caccataaac	aatttggtca	ttaacatcag	ttctatagac	ggtgcaaaga	1680
aggcaaaaaat	agaaacccaaa	gctacgtcaa	aaaatctgac	tttatctgga	accatcactt	1740
tattggaccc	gacgggcacg	ttttatgaaa	atcatagttt	aagaaatcct	cagtcctacg	1800
acatcttaga	gctcaaagct	tctggaactg	taacaagcac	cgcagtgact	ccagatccta	1860
taatgggtga	gaaattccat	tacggctatc	agggaaacttg	gggcccatt	gtttggggga	1920
caggggcttc	tacgactgca	accttcaact	ggactaaaac	tggctatatt	cctaattccc	1980
agcgtatcgg	ctcttttagtc	cctaatagtc	tatggaatgc	atttatagat	attagctctc	2040
tccattatct	tatggagact	gcaaacgaag	ggttgcaggg	agaccgtgct	ttttggtgtg	2100
ctggattatc	taacttcttc	cataaggata	gtacaaaaac	acgacgcggg	tttcgccatt	2160
tgagtgggcg	ttatgtcata	ggaggaaacc	tacatacttg	ttcagataag	attcttagtg	2220
ctgcattttg	tcagctcttt	ggaagagata	gagactactt	tgtagctaag	aatcaaggta	2280
cagtctacgg	aggaactctc	tattaccagc	acaacgaaac	ctatatctct	cttccttgca	2340
aactacggcc	ttgttcggtg	tcttatgttc	ctacagagat	tcctgttctc	ttttcaggaa	2400
accttagcta	caccataacg	gataacgatc	tgaaaaccaa	gtatacaaca	tatcctactg	2460
ttaaaggaag	ctgggggaat	gatagtttcg	ctttagaatt	cggtggaaga	gctccgattt	2520
gcttagatga	aagtgtctta	tttgagcagt	acatgccctt	catgaaattg	cagtttgtct	2580
atgcacatca	ggaaggtttt	aaagaacagg	gaacagaagc	tcgtgaattt	ggaagtagcc	2640
gtcttgtgaa	tcttgcctta	cctatcgggg	tccgatttga	taaggaatca	gactgccaa	2700

atgcaacgta	caatctaact	cttggttata	ctgtggatct	tgttcgtagt	aaccccgact	2760
gtacgacaac	actgcaatt	agcgggtgatt	cttggaacac	cttcggtacg	aatttggcaa	2820
gacaagcttt	agtccttcgt	gcaggaacc	atTTTTgctt	taactcaa	tttgaagcct	2880
ttagccaatt	ttcttttgaa	ttgcgtgggt	catctcgcaa	ttacaatgta	gacttaggag	2940
caaaatacca	attctaattgc	gttagctttg	gtaaagagct	ccatacatcg	aagggaaaag	3000
agcttttaag	atTTcttgaa	ggctcttttc	gatttcgatt	tccatttttag	tgTTTTgcta	3060
aaacactttc	taatTTTTtt	cttttgTTTT	ctacattgaa	aaaaagagag	ttacggcagc	3120
tgtaaagttt	ttaatattgc	tccctttgtt	ccattttatgt	agcgttcaga	ctttgcacta	3180
aaacgaggg	gtcatatgag	atcgtctttt	tccttgttat	taatatcttc	atctctagcc	3240
tttctctct	taatgagtgt	ttctgcagat	gctgccgatc	tcacattagg	gagtcgtgac	3300
agttataatg	gtgatacaag	caccacagaa	tttactccta	aagcggcaac	ttctgatgct	3360
agtggcacga	cctatatctt	cgatggggat	gtctcgataa	gccaaagcag	gaaacaaacg	3420
agcttaacca	caagttgttt	ttctaacact	gcaggaaatc	ttaccttctt	agggaaacgga	3480
ttttctcttc	atTTtgacaa	tattatttcg	tctactgttg	caggtgttgt	tgTTtagcaat	3540
acagcagctt	ctgggattac	gaaattctca	ggattttcaa	ctcttcggat	gcttgcaagt	3600
cctaggacca	caggtaaagg	agccattaaa	attaccgatg	gtctgggtgt	tgagagtata	3660
gggaatcttg	atcttaatga	aaatgcctct	agtgaatg	ggggagccat	caatacgaag	3720
actttgtctt	tgactgggag	tacgcggttt	gtagcgttcc	ttggcaatag	ctcgtcgcaa	3780
caagggggag	cgatctatgc	ttctgggtgac	tctgtgattt	ctgagaatgc	aggaatcttg	3840
agcttcggaa	acaacagtgc	gacaacatca	ggaggcgcga	tctctgctga	agggaaacctt	3900
gtgatctcca	ataacaaaa	tatctttttt	gatggctgca	aagcaactac	aaatggcgga	3960
gctattgatt	gtaacaaagc	aggggcgaac	ccagacccta	tcttgactct	ttcaggaaat	4020
gagagcctgc	atTTtctgaa	taacacagca	ggaaatagtg	gaggtgcat	ttataccaaa	4080
aaattggtgt	tatcttcagg	acgaggagga	gtgttatttt	ctaacaacaa	agctgcgaat	4140
gctactccta	aaggaggggc	aattgcgatt	ctagattctg	gagagattag	catttctgca	4200
gatctcggca	atatcatttt	cgagggcaat	actacgagca	ctacaggaag	tcctgcgagt	4260
gtgaccagaa	atgctataga	tcttgcatcg	aatgcaaaat	ttttaaatct	ccgagcgact	4320
cggggaaata	aagttatttt	ctatgatcct	atcacgagct	caggagctac	tgataagctc	4380
tctttgaata	aagctgacgc	aggatctgga	aatacctatg	aaggctacat	cgttttctct	4440
ggagagaaac	tctcagaaga	ggaacttaag	aaacctgaca	atctgaagtc	tacatttaca	4500
caggctgtag	agcttgctgc	aggtgcctta	gtattgaaag	atggagtgc	tgtagttgca	4560
aatactataa	cgaggtcga	gggatcgaaa	gtcgttatgg	atggagggac	tacttttgag	4620
gcaagcgctg	agggggtcac	tctcaatggc	ctagccatta	atatagattc	cttagatggg	4680
acaaataaag	ctatcattaa	ggcgacggca	gcaagtaagg	atgttgccct	atcagggcct	4740
atcatgcttg	tagatgctca	ggggaactat	tatgagcatc	ataatctcag	tcaacagcag	4800
gtctttcctt	taatagagct	ttctgcacaa	ggaacgatga	ctactacaga	tatccccgat	4860
accccaattc	taaatactac	gaatcactat	gggtatcaag	ggaactggaa	taattgtttg	4920
ggtcgacgat	gcaactgcaa	aaacaaaaaa	tgctacctta	acttggaacta	aaacaggata	4980
caagccgaat	ccagaacgtc	agggaccttt	ggttccta	agcctgtggg	gttcttttgt	5040
cgatgtccgc	tccattcaga	gcctcatgga	ccggagcaca	agttcgttat	cttcgtcaac	5100
aaatttggtg	gtatcaggaa	tcgcggactt	tttgcatgaa	gatcagaaa	gaaaccaacg	5160
tagttatcgt	cattctagcg	cggttatgct	attaggagga	ggattcttca	cggcttctga	5220
aaatttcttt	aattttgctt	tttgtcagct	ttttggctac	gacaaggacc	atcttgtggc	5280
taagaaccat	acccatgtat	atgcaggggc	aatgagttac	cgacacctcg	gagagtctaa	5340
gaccctcgct	aagattttgt	caggaaattc	tgactcccta	ccttttgtct	tcaatgctcg	5400
gtttgcttat	ggccataccg	acaataacat	gaccacaaag	tacactggct	attctcctgt	5460
taagggaagc	tggggaaatg	atgccttcgg	tatagaatgt	ggaggagcta	tcccggtagt	5520
tgcttcagga	cgtcggctct	gggtggatac	ccacacgcca	tttctaaacc	tagagatgat	5580
ctatgcacat	cagaatgact	ttaaggaaaa	cggcacagaa	ggcgttctt	tccaaagtga	5640
agacctcttc	aatctagcgg	ttcctgtagg	gataaaattt	gagaaattct	ccgataagtc	5700
tacgtatgat	ctctccatag	cttacgttcc	cgatgtgatt	cgtaatgatc	caggctgcac	5760
gacaactctt	atggtttctg	gggattcttg	gtcgacatgt	ggtacaagct	tgtctagaca	5820
agctcttctt	gtacgtgctg	gaaatcatca	tgctttgtct	tcaaactttg	aagttttcag	5880
tcagtttgaa	gtcgagttgc	gaggttcttc	tcgtagctat	gctatcgatc	ttggaggaag	5940
attcggattt	taatcctaag	ttttccaacg	agatagcatc	agggtaagcc	agggctctat	6000
gtaagagatt	tcatagagcc	ctctctttgt	cttgcttttt	gtattttatt	tttatatttc	6060
gtgaatccgt	tgttccaatg	ttcgaaaggt	atcctagatg	agattgctgt	tgtcttgtcc	6120
tatgcttttt	atagctgcat	gtgcctcatt	ttttggcttt	caggaagaaa	tgcaaggcag	6180
aaatatacaa	tctcttgatg	caaattgctt	tagtctaggg	gaactttttt	ctatttctac	6240
gaagggagtg	tcttgtctag	aactccatag	ggagatcgca	cgctaaatat	gagaatataa	6300

tatgaagact	tcagtttcta	tgttggttggc	cctgcttttgc	tcggggggcta	gctctatttgt	6360
actccatgcc	gcaaccactc	cactaaatcc	tgaagatggg	tttattggggg	agggcaatac	6420
aaatactttt	tctccgaaat	ctacaacgga	tgctgcagga	actacctact	ctctcacagg	6480
agaggttctg	tatatagatc	cggggaaagg	tggttcaatt	acaggaactt	gctttgtaga	6540
aactgctggc	gatctttacat	ttttaggtaa	tggaaatacc	ctaaagtcc	tgctcggtaga	6600
tgcaggtgct	aatatcgcg	ttgctcatgt	acaaggaagt	aagaatttaa	gcttcacaga	6660
tttcctttct	ctggtgatca	cagaatctcc	aaaatccgct	gttactacag	gaaaaggtag	6720
cctagtcagt	ttaggtgcag	tccaactgca	agatataaac	actctagttc	ttacaagcaa	6780
tgcctctgtc	gaagatgggtg	gcgtgattaa	aggaaaactcc	tgcttgattc	agggaaatcaa	6840
aaatagtgcg	atTTTTggac	aaaatacatc	ttcgaaaaaa	ggagggggcga	tctccacgac	6900
tcaaggactt	accatagaga	ataacttagg	gacgctaaag	ttcaatgaaa	acaaagcagt	6960
gacctcagga	ggcgcccttag	atttagggagc	cgcgctctaca	ttcactgcga	accatgagtt	7020
gatatTTTca	caaaataaga	cttctgggaa	tgctgcaaat	ggcggagcca	taaattgtctc	7080
aggggacctt	acatttactg	ataacacttc	tttgttactt	caagaaaata	gcacaatgca	7140
ggatgggtgga	gctttgtgta	gcacaggaac	cataagcatt	accggtagtg	attctatcaa	7200
tgtgatagga	aatacttcag	gacaaaaagg	aggagcgatt	tctgcagctt	ctctcaagat	7260
tttgggaggg	cagggaggcg	ctctcttttc	taataacgta	gtgactcatg	ccaccctct	7320
aggaggtgcc	atTTTTtatca	acacaggagg	atccttgcat	ctcttcactc	aaggaggggga	7380
tatcgtattc	gaggggaatc	aggtcactac	aacagctcca	aatgctacca	ctaagagaaa	7440
tgtaattcac	ctcgagagca	ccgcgaagtg	gacgggactt	gctgcaagtc	aaggtaacgc	7500
tatctatttc	tatgatccca	ttaccaccaa	cgatacggga	gcaagcgata	acttacgtat	7560
caatgaggtc	agtgc aaatc	aaaagctctc	gggatctata	gtattttctg	gagagagatt	7620
gtcgacagca	gaagctatag	ctgaaaatct	tacttcgagg	atcaaccagc	ctgtcacttt	7680
agtagagggg	agcttagtac	ttaaacaggg	agtgaccttg	atcacacaag	gattctcgca	7740
ggagccagaa	tccacgcttc	ttttggatct	ggggacctca	ttataagctt	ctacagaaga	7800
tattgtcatc	acaaatTTtat	ctataaatgc	cgataccatt	tacggaaaga	atcctatcaa	7860
tattgtagct	tcagcagcga	ataagaacat	taccctaaca	ggaaccttag	cacttgtaaa	7920
tgcagatgga	gctttctatg	agaaccatac	cttgcaagac	tctcaagact	atagctttgt	7980
aaagttatct	ccaggagcgg	gagggactat	aattactcaa	gatgcttctc	agaagcctct	8040
tgaagtagct	ccttctagac	cacattatgg	ctatcaagga	cattggaatg	tgcaagtcac	8100
cccaggaacg	ggaactcaac	cgagccaggc	aaatttagaa	tgggtgcgga	caggatacct	8160
tccgaatccc	gaacggcaag	gatcttttag	tcccaatagc	ctgtgggggtt	cttttggtga	8220
tcagcgtgct	atccaagaaa	tcattggtaaa	tagtagccaa	atcttatgtc	aggaacgggg	8280
agtctgggga	ctcgaatttg	ctaatttcct	acatagagat	aaaattaatg	agcacggcta	8340
tcgccatagc	ggtgtcggtt	atcttggtgg	agttggcact	catgcttttt	ctgatgctac	8400
gataaatgcg	gctttttgcc	agctcttcag	tagagataaa	gactacgtag	tatccaaaaa	8460
tcattggaact	agctactcag	gggtcgtatt	tcttgaggat	accctagagt	ttagaagtcc	8520
acagggattc	tatactgata	gctcctcaga	agcttgctgt	aaccaagtcg	tcactataga	8580
tatgcagttg	tcttacagcc	atagaaataa	tgatatgaaa	accaaataca	cgacatatcc	8640
agaagctcag	ggatcttggg	caaatgatgt	ttttgggtctt	gagtttggag	cgactacata	8700
ctactaccct	aacagtactt	ttttatttga	ttactactct	ccgtttctca	ggctgcagtg	8760
cacctatgct	caccaggaag	acttcaaaga	gacaggaggt	gaggttcgtc	actttactag	8820
cggagatctt	ttcaattttag	cagttcctat	tggcgtgaag	tttgagagat	tttcagactg	8880
taaaagggga	tcttatgaac	ttacccttgc	ttatgttcct	gatgtgattc	gcaaagatcc	8940
caagagcacg	gcaacatttg	ctagtggagc	tacgtggagc	acccacggaa	acaatctctc	9000
cagacaagga	ttacaactgc	gtttagggaa	ccactgtctc	ataaatcctg	gaattgaggt	9060
gttcagtcac	ggagctattg	aattgcgggg	atcctctcgt	aattataaca	tcaatctcgg	9120
gggtaaatac	cgattttaat	agggaactga	gagttcctta	ttgtagagag	tattttacaag	9180
gattttgaga	cgaaagagat	ttcttggtgt	aggatatctc	ccacagggtc	tagttcaatt	9240
tctatagttc	atggggtttc	tttttttata	aagaagaaac	cccatgtctg	acgagacctc	9300
acctggatct	attgcattct	ctatggtaag	ggatccatga	cttgacacag	gaggttcatt	9360
ctcatgtcta	agtcagaggt	tagaagggag	gttttttagg	tttgctgagc	tttaagaaga	9420
agaaaaatcg	actatctgct	tctcggcggt	catacacccc	atagagctgc	caatgttcga	9480
agatcttcgt	ccctagaatc	atctggtatt	ctaggtagtt	cggagtgtcc	tggcgatgcc	9540
agccatagcg	taaggataag	cggtaatcc	aacagggatg	aggtcgtaca	aataatttcc	9600
ctaaaatgag	attcctatga	tcagagagag	gggagtctaa	aagctgggtca	atgggacggc	9660
tgacatctaa	aatgaagttc	tccctgtcac	acttaatcag	gctgtatttg	cttctatgca	9720
gggattctag	agtcatagcc	acattgtcat	ttccgatcca	ctcccaacgt	atgttcatgt	9780
gatcccaaca	gtgctttttc	caaatccatt	cagcatctaa	ggagactgta	tttttctttc	9840
caaaaggtag	agatagctcg	catgcagttt	tgggaaacgt	gggtttgctt	tctgtattgc	9900

tcaagatgtg	ggtagtccac	agcttcgcat	ggattctcgg	gaatcgaggg	ttagtcttac	9960
tcagtaccga	ggtatctata	cccgctttca	gaagggttaa	ggagtgaag	gcattcttgaa	10020
tagaaaagat	ataatgatct	tcattcttag	ctagaggacg	agtctctgta	atgaaggtaa	10080
cgaacggctc	tataatatgg	cgtctttgaa	tgtaggactt	atgtaataga	aagcgataat	10140
caagttgtag	cttcgcggaa	agctgactat	ggcgcgagga	gatctcagga	acatcgctat	10200
agtaaatacag	agaactccct	aggggtggagg	agagcgttcc	tataggtaga	ggcacagttt	10260
tatggagctt	agggcgcgca	gcaagacgta	gtgaagagaa	attctcgcca	acgatatgat	10320
cgctaaaagc	aaagtttaaa	taccacatt	ctacgatgtt	ttcaaggta	actcccgtat	10380
tataaataga	aatcggttac	tgccttaatg	ttaaataagg	gagctcttg	ttggcatttt	10440
ggaaagagtt	taccttaaca	gaagaggtga	gatacccttc	aaaatagttg	tcattccaag	10500
tgcaatcgac	acgtgtgggg	cctgtatttt	tcaacatgaa	gttggtgggg	aaaatgtcag	10560
caacagtttc	ccaactatcg	ctgagatggg	attctccaga	aaaatttaca	tgcttatgcg	10620
tgaagcagaa	atctccgtgt	aggcgatagc	gatcatgagc	ttctgccata	tcgatagcaa	10680
ggcgggtggg	ataatagctt	ttcatattga	agacattctc	aggaacctgc	ttctgagaac	10740
aatggaggtt	gaatcccatt	ccgacgccat	gcttgaaaaa	gctatccaag	aaaaatgtcg	10800
aggagaaatg	cttcctagaa	atcggcgagt	agctcatccc	caaataggat	cccagaaatc	10860
ctcctgttcc	tcctcgaaag	tttatcgagg	gcttagggat	ctccataggc	atgatagaaa	10920
atggaggtaa	gaaaagtatc	ggaatgcgac	acacccttaa	tggtgtcttc	cctatagaaa	10980
gaagactatc	tgaagaatat	tccaggtaat	ctccggagag	gcacaggtct	tttttgggac	11040
cctcggaggt	agagatatat	cccttccgaa	tgactatggt	ttctgggggt	agagtgatca	11100
tagaccccc	tagaaaccaa	ggatacatcg	cgaatcttcc	attagtaaga	agacaagagt	11160
ctgtatcttc	gtaatactct	aggtaatcac	aaactagggt	ttttgcccta	tagttcacca	11220
taacattgcc	atgtgcgaca	agcttcaggc	tttgaccac	agtattttct	acatacactt	11280
tattggcttg	tatccgcagg	ttgttatgga	tattcaatac	cccatcttcg	atggtcacaa	11340
tcccagaaac	actcttaaa	tgactaagat	aggagttttt	ctttttcaca	gcctcttgat	11400
gagtcaaagc	atcagctgag	gaacccataa	gaacaaagga	agctagaaat	aagaagcaac	11460
gtttcataag	acgtagggtg	gggttactcc	acaattttta	tgagtaagcc	tgcaaggact	11520
gggaaatttt	ttgcatctcc	ttccgtcatc	agttgtatca	ataaacggat	atcttcggaa	11580
gacttcgagg	tggttagtgt	ctctagaata	tccaacatga	gcttcgtacg	gctttctggg	11640
gtgacctgat	aacgtagata	gggcatgctg	ggatggggtc	tttggttttc	cgtgtccaca	11700
aataacaagg	tttcttgaat	tagctttttt	gcataatcat	ggagagaacg	ttttttttca	11760
ggatcttttg	tgagattata	aatagcaaga	tctgcatagg	cgcgatgat	aggttctcca	11820
ggaagcttcg	cagcttgga	aagtagatct	aaggcttctc	gatgtgaggt	gtgacttaaa	11880
aaagaaatcg	caatagtggc	aagctgagtt	ttctgactcg	ccaaaagctt	ataaatcacg	11940
gggaggtaag	cttctttagg	taggcggaag	agaaacgtaa	ggatctgctc	ttcaagacct	12000
cgggttgttg	agagcaacct	ttccctctcc	tggggatctt	gagggactat	gatgttcacc	12060
cgcttccaat	tttgtaaagt	acgcccctta	gagaaactca	aggctagagt	ctcattataa	12120
tgtggttgga	caagcctttc	ggtaatgtat	tccagtagtt	taggggtgtc	acaccctaac	12180
tctaagagag	ctaaagctac	attcaacttg	gcttcgctgt	tcttagtttt	taggaatatc	12240
ggcagggcaa	tcggaatccc	tatctcagag	ggtagatgcc	gtaaggcata	cagggctcga	12300
ggccgctcct	caagtgttg	cttttttatc	acgggaagag	cgtcctcttc	tttcccaaaa	12360
gcaattaaag	cttgagctgc	tgctaaagtg	acatccacat	caggcttctg	caattgcttt	12420
tttatattgt	agtagctctg	accatcctta	agcttcccta	aagcataaag	aatagcttct	12480
tgatcttgag	gagacgcact	cgttagcaaa	ttcctaagtg	tcggaagaaa	gcgtttttgt	12540
tggtattctc	cgatctgcaa	agctgtggca	ctccgaatcg	cgcttttctt	ggcagctaag	12600
agatcccga	tataagcatc	agattcttca	gtctccaagc	gtaggaatat	tgccgcagat	12660
aggcattgga	tttcttcggg	aagcttatga	atgaaagaat	gtagatgatc	aatgacttta	12720
gtgttcttca	aattagcaag	tctataggcg	gcttctaagc	ggatgacagg	ataggagat	12780
gctaaagctt	taaacagtaa	gtcgtcagaa	gttttcccaa	gatgtcctga	gactgccgat	12840
aaaaccagta	gctgtgcag	ggggtctgca	gtttccatag	cttgggagag	cacgtccaag	12900
gcttctgaag	atcccgcag	gcctgtccca	atgatgggtc	tttttctagt	ttgcggatct	12960
gaggagtgga	tgcttttgctt	gagatagtct	tctccgattt	ttcttaaaac	gaagaagtca	13020
tgatcacctg	aggcatctag	agcttccaga	tatgttgcta	aggcctgctg	tgtagattgc	13080
gtacttata	aaaggatctt	atgacctaca	gactcaggga	atttagcaac	aagagaaatg	13140
ggaagactac	acaataaaag	tccaaagaga	gttagatgga	atagtcccat	agatcgatgt	13200
tcaactctc	tagcaagtat	ttcaatgttt	ggataggagg	accttgaaca	ttataaacac	13260
atccatggac	ctttttcaaa	atcaagccac	catggcaaac	gtcataagcg	ccacaattat	13320
ttaatgttcc	tacagtgtcg	atataagact	ctatgcggtg	atcaggaatc	atagtaagtg	13380
aaatctgaga	agtctctgac	cctgtgagga	gttttccctt	atgtaatacg	gcaatactcg	13440
tgaccacatc	atgcgtctga	ttcctcaagg	tctttaacat	ctggatagcg	tctgctttgt	13500

cttgagggttt	tgtgaaaata	cggccatcgt	aagaaacaat	agtatcgcca	gtgaggataa	13560
tacagtcaca	aggcgaatgt	agctcagaaa	ctgcataggc	cttttgtgcg	gcaagttctt	13620
gtgtataggc	tataggatcc	ccagagtagc	tgactttact	ctcatcaaaa	tttgaaggaa	13680
tgacagtaaa	gggaacacga	aatttttcta	aaataaattt	tcttcttggc	gaagaagacc	13740
ctaaaactaa	aggaaggac	atagaataaa	agctcctcgt	gttagatata	ttacaacaat	13800
tgcttatgac	ctgcagtata	gtctaccata	gttccatcga	agaatgtaat	cttatcttta	13860
tcaaagatca	ataacttcgt	agcacaatct	tgaatcagtc	ctctgtcgtg	agagacaaaa	13920
atcgctgtgc	ccttatagtc	attgatagcc	caagaaagag	cagacacaga	ctctaagtct	13980
aagtggttgt	tcgcttcac	aaggataagg	acattatggt	tttctagcat	catccccgcc	14040
atgagaagac	gagctgtttc	tcctccagat	aatgcttgga	tttgcttgaa	agcatcatcg	14100
cctccaaaaa	gcattttccc	taacacactg	cggattttct	gacgtttaat	tccgggttttg	14160
cgattgcgta	gccactcaaa	tagcgtttct	tgaccacaat	cagctagaac	atcgctgtgg	14220
ttttgaggaa	aatatgaaca	gatagcttga	tggcctaact	tgatacttcc	tgaagaagga	14280
gcctcaaac	ctgcaagtaa	cttcattaat	gtagttttac	ccaatccatt	gttccccgata	14340
ataccaagct	tgtctccttg	ataaatctct	aaagaaaaag	gatggattac	ctgatgatcc	14400
ccataatcct	ttgtaatcgc	ttctaaagac	aaaacgactt	tccctgagga	tttgtcagat	14460
agggggaaac	gaatgtaagg	acgttgata	ttggattttt	ttaattcttg	tggctgaagc	14520
ttcttaatct	ctcttaatcg	agactgcact	tgactcgctc	gtgatccgc	accaaattta	14580
gcaacaaatt	ccttaagctg	agaaattttc	tttctcttag	atgtgatgtc	ggccttttct	14640
tgctcgcgag	acgcggtttt	catctctacc	atatcgctcat	agtttccagg	gtagataatg	14700
atcggtgctg	aatcaatgtc	agcaatgtga	gtcgtaattg	tatttaagaa	atgacggctg	14760
tgactgacta	caatgacagt	gccttcataa	tcttttaaaa	agtttcccag	ccaattaatg	14820
gaatagaggt	ccaagtgggt	tgttggtcca	tcaagaagaa	gtgcttcggg	gtgaccaaag	14880
agagcctggc	aaagaagaac	tcgaaattgt	aggtctatgg	gaatcatagc	cattttctta	14940
tcaaacatct	cattggggat	gccaatgcct	gtgaggagtt	cttcggcttc	tgaatctgct	15000
cggtagccat	tttctcgcgc	gatgatctct	tcaatttcac	caagctccat	tccaatggcg	15060
tcagtaaaat	cttgtagata	gagattatca	cggcggttgta	aagcttccca	aagacgagta	15120
tttcccataa	tgacacaatc	taagactggt	gtgtcgtgaa	agctatcgat	attttgacgc	15180
aggatcccca	cttttttagg	taaggaaatc	gaacctcttg	taggttctat	cattcccata	15240
atgattttta	aaaggggtga	ctttcctgcg	ccgttaggac	cagtaagacc	gtagcagttc	15300
ccgggggtga	aaacgacgga	aacatcatcg	aataaaattc	gagtgcctaa	agatttgcca	15360
attttatcta	atactatgct	catagcagac	agcatacaaa	agtgtgctt	agagtacaag	15420
agctttgccc	tgttctctta	ggcatgggga	tgggcttctt	ggtgggtctg	tttttttaac	15480
tttacagaga	cttgcggtata	gaccgttggt	gtctctaaag	aactatgacc	aagaagtgct	15540
tggattgttt	ttaaattccat	accactctct	agccaatggg	tggctatagt	gtgacggatt	15600
gtatgggggg	tgatgtgccc	tgaaagtcca	gaacgtcgaa	gatattcttg	aaaacttctg	15660
tcaatagatc	gtgttgaaat	gcgcctccca	aagcgattga	gaaagatggc	ttgaggatcc	15720
ttttccaaac	gctttctatc	cggatgggtc	aggtagattt	ggatccattg	tatggcattc	15780
gatgtcacgg	gaataatcct	ttcttttttc	cctttccac	ggatgcgaat	cagatgagta	15840
ctcaaatcaa	agtcctgttt	attaacagcg	acaatctcac	taatcctcaa	acccgaacta	15900
tagaacagct	ccatgagaca	gcgatcacga	agtcctgtgat	atttagaaat	gtcaggagtc	15960
gccatcagca	cttcaacttg	cgcataagtc	atcggggaag	gcagctcctt	aggaagacga	16020
ggtccgtgga	tagtttccgc	aggattttcc	aaaagaatct	tttgaataac	acagtaatgg	16080
gcaaagcttt	taatggaaga	gaggcaacgc	ttaattgttc	tcttagcttt	gccattttct	16140
atcagtttctg	cgatgtacat	gcgtacatgc	tctttggtga	ataaggaaaa	aggaagttca	16200
gagactttgc	gcttctctgt	ggctaactgt	aaaggagaag	aaggagcgag	gttaccacgt	16260
tcctctaaaa	aaattttcaa	tccatttaaga	tctagacaat	aatttcttaa	tgtatgcgga	16320
gaggcacttt	ttaccatttt	caaatagtct	aagaacgaat	agatagaggc	aatcataact	16380
tctctttacc	ttacaataaa	gatcgtaaaa	agacttcttc	ttagcttttag	gaaggctagc	16440
ttcttact						16448

//

LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG
SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW
(EP) AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE
(OA) BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG
(AP) GH GM KE LS MW MZ SD SL SZ TZ UG ZW
(EA) AM AZ BY KG KZ MD RU TJ TM

Publication Language: English

Filing Language: English

Fulltext Word Count: 101768

Fulltext Availability:

Detailed Description

Detailed Description

... G)

Campylobacterjejuni NCTC 11 168 Y17167 tuf
Campylobacterjejuni NCTC 11 168 CJ11168X2 tuf (EF-G)
Chlamydia pneumoniae **CWL029** AE001592 tuf
Chlamydia pneumoniae **CWL029** AE001639 tuf (EF-G)
Chlamydia trachomatis M74221 tuf
Chlamydia trachomatis D/UW-3/CX AE001317 tuf (EF-G)
Chlamydia trachomatis D/UW-3/CX...81-176 U03121 recA
Campylobacterjejuni NCTC 11 168 AL139079 recA
Chlamydia trachomatis L2 U16739 recA
Chlamydia trachomatis D/UW-3/CX AE001335 recA
Chlamydophila pneumoniae **CWL029** AE001658 recA
Chloroflexus aurantiacus J-1041 AF037259 recA
Clostridium acetobutylicum M94057 recA
Clostridium perfringens 13...

1/3,KWIC/14 (Item 10 from file: 349)

DIALOG(R) File 349:PCT FULLTEXT

(c) 2002 WIPO/Univentio. All rts. reserv.

00778694

ISOPRENOID BIOSYNTHESIS

BIOSYNTHESE D'ISOPRENOIDES

Patent Applicant/Inventor:

BACHER Adelbert, Konigsbergerstr. 74, D-85748 Garching, DE, DE

(Residence), DE (Nationality)

ZENK Meinhard, Carl-von-Ossietzky-Str. 11, D-06114 Halle/Saale, DE, DE

(Residence), DE (Nationality)

EISENREICH Wolfgang, Romerhofweg 51a, D-85748 Garching, DE, DE

(Residence), DE (Nationality), (Designated only for: US)

FELLERMEIER Monika, Halserspitzstr. 12, D-81673 Munchen, DE, DE

(Residence), DE (Nationality), (Designated only for: US)

FISCHER Markus, Ruppertstr. 10, D-80337 Munchen, DE, DE (Residence), DE

(Nationality), (Designated only for: US)

HECHT Stefan, Engelhofstr. 6, D-85386 Dietersheim, DE, DE (Residence), DE

(Nationality), (Designated only for: US)

HERZ Stefan, Clemensstrasse 12, D-80803 Munchen, DE, DE (Residence), DE

(Nationality), (Designated only for: US)

KIS Klaus, Reutberger Strasse 16, D-81371 Munchen, DE, DE (Residence), DE

(Nationality), (Designated only for: US)

LUTTGEN Holger, Schleissheimer Strasse 13, D-85748 Garching, DE, DE

(Residence), DE (Nationality), (Designated only for: US)

ROHDICH Felix, Moosburger Strasse 16, D-85406 Zolling, DE, DE (Residence)

, DE (Nationality), (Designated only for: US)

SAGNER Silvia, Hess Strasse 12, D-81673 Munchen, DE, DE (Residence), DE

(Nationality), (Designated only for: US)

SCHUHR Christoph A, Zugspitzweg 22, D-85748 Garching, DE, DE (Residence),

DE (Nationality), (Designated only for: US)

WUNGSINTAWEEKUL Juraithip, Reischlweg 8A, D-80939 Munchen, DE, DE

(Residence), TH (Nationality), (Designated only for: US)

Legal Representative:

WACHERSHAUSER Gunter, Tal 29, D-80331 Munchen, DE

Patent and Priority Information (Country, Number, Date):

Patent: WO 200111055 A1 20010215 (WO 0111055)

SYSTEM:OS - DIALOG OneSearch

File 155:MEDLINE(R) 1966-2002/Sep W5

*File 155: Alert feature enhanced for multiple files, duplicates removal, customized scheduling. See HELP ALERT.

File 349:PCT FULLTEXT 1983-2002/UB=20021003,UT=20020926

(c) 2002 WIPO/Univentio

File 5:Biosis Previews(R) 1969-2002/Oct W1

(c) 2002 BIOSIS

*File 5: Alert feature enhanced for multiple files, duplicates removal, customized scheduling. See HELP ALERT.

File 73:EMBASE 1974-2002/Oct W1

(c) 2002 Elsevier Science B.V.

*File 73: Alert feature enhanced for multiple files, duplicates removal, customized scheduling. See HELP ALERT.

Set Items Description

--- -----

Cost is in DialUnits

?ds

Set Items Description

S1 24 CWL029 (10N) CHLAMYDI?

S2 16 RD (unique items)

?t s1/3,kwic/5-16

1/3,KWIC/5 (Item 1 from file: 349)

DIALOG(R)File 349:PCT FULLTEXT

(c) 2002 WIPO/Univentio. All rts. reserv.

00841553 **Image available**

CHLAMYDIA TRANSMEMBRANE PROTEIN AS ANTIGEN, CORRESPONDING DNA FRAGMENTS AND USES THEREOF

ANTIGENES DE \$I(CHLAMYDIA) ET FRAGMENTS D'ADN CORRESPONDANTS, ET LEUR UTILISATION

Patent Applicant/Assignee:

AVENTIS PASTEUR LIMITED, Connaught Campus, 1755 Steeles Avenue West,
Toronto, Ontario M2R 3T4, CA, CA (Residence), CA (Nationality), (For
all designated states except: US)

Patent Applicant/Inventor:

MURDIN Andrew D, 11 Forest Hill Drive, Richmond Hill, Ontario L4B 3C2, CA
, CA (Residence), GB (Nationality), (Designated only for: US)

OOMEN Raymond P, 29 Kennedy Street West, Aurora, Ontario L4G 2L6, CA, CA
(Residence), CA (Nationality), (Designated only for: US)

WANG Joe, 51 Aspenwood Drive, Toronto, Ontario M2H 2E8, CA, CA
(Residence), CA (Nationality), (Designated only for: US)

DUNN Pamela, 97 Rosebury Lane, Woodbridge, Ontario L4L 3Z1, CA, CA
(Residence), GB (Nationality), (Designated only for: US)

Legal Representative:

NGUYEN Thuy H (et al) (agent), Smart & Biggar, 900-55 Metcalfe Street,
P.O. Box 2999, Station D, Ottawa, Ontario K1P 5Y6, CA,

Patent and Priority Information (Country, Number, Date):

Patent: WO 200175114 A2-A3 20011011 (WO 0175114)

Application: WO 2001CA462 20010404 (PCT/WO CA0100462)

Priority Application: US 2000194477 20000404

Designated States: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU

CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR

KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE

SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

(EP) AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR

(OA) BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

(AP) GH GM KE LS MW MZ SD SL SZ TZ UG ZW

(EA) AM AZ BY KG KZ MD RU TJ TM

Publication Language: English

Filing Language: English

Fulltext Word Count: 18024

Fulltext Availability:

Detailed Description

Detailed Description

... pCACPNM643 containing the transmembrane protein gene.
The myosin heavy chain homolog gene was amplified
from **Chlamydia pneumoniae** genomic DNA strain **CWL029** by
polymerase chain reaction (PCR) using a 51 primer
(

1/3,KWIC/6 (Item 2 from file: 349)

DIALOG(R)File 349:PCT FULLTEXT

(c) 2002 WIPO/Univentio. All rts. reserv.

00841552 **Image available**

**CHLAMYDIA MYOSIN HEAVY CHAIN HOMOLOG AS ANTIGEN, CORRESPONDING DNA
FRAGMENTS AND USES THEREOF**

**ANTIGENES DE CHLAMYDIA, FRAGMENTS CORRESPONDANTS D'ADN, ET LEURS
UTILISATIONS**

Patent Applicant/Assignee:

AVENTIS PASTEUR LIMITED, Connaught Campus, 1755 Steeles Avenue West,
Toronto, Ontario M2R 3T4, CA, CA (Residence), CA (Nationality), (For
all designated states except: US)

Patent Applicant/Inventor:

MURDIN Andrew D, 11 Forest Hill Drive, Richmond Hill, Ontario L4B 3C2, CA
, CA (Residence), GB (Nationality), (Designated only for: US)

OOMEN Raymond P, 29 Kennedy St. W., Aurora, Ontario L4G 2L6, CA, CA
(Residence), CA (Nationality), (Designated only for: US)

WANG Joe, 51 Aspenwood Drive, Toronto, Ontario M2H 2E8, CA, CA
(Residence), CA (Nationality), (Designated only for: US)

DUNN Pamela, 97 Rosebury Lane, Woodbridge, Ontario L4L 3Z1, CA, CA
(Residence), GB (Nationality), (Designated only for: US)

Legal Representative:

NGUYEN Thuy H (et al) (agent), Smart & Biggar, 900-55 Metcalfe Street,
P.O. Box 2999, Station D, Ottawa, Ontario K1P 5Y6, CA,

Patent and Priority Information (Country, Number, Date):

Patent: WO 200175113 A2-A3 20011011 (WO 0175113)

Application: WO 2001CA461 20010404 (PCT/WO CA0100461)

Priority Application: US 2000194475 20000404

Designated States: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU

CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR

KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE

SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

(EP) AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR

(OA) BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

(AP) GH GM KE LS MW MZ SD SL SZ TZ UG ZW

(EA) AM AZ BY KG KZ MD RU TJ TM

Publication Language: English

Filing Language: English

Fulltext Word Count: 18028

Fulltext Availability:

Detailed Description

Detailed Description

... the myosin heavy chain homolog
gene.

The myosin heavy chain homolog gene was amplified
from **Chlamydia pneumoniae** genomic DNA strain **CWL029** by
polymerase chain reaction (PCR) using a 5' primer
(5f ATAAGAATGCGGCCGCCACCATGCATGACGCACTTCTAAGCA 3f; SEQ ID No...

1/3,KWIC/7 (Item 3 from file: 349)

DIALOG(R)File 349:PCT FULLTEXT

(c) 2002 WIPO/Univentio. All rts. reserv.

00841551 **Image available**

CHLAMYDIA ANTIGENS AND CORRESPONDING DNA FRAGMENTS AND USES THEREOF

**ANTIGENE <I>CHLAMYDIA</I>, FRAGMENTS D'ADN CORRESPONDANTS, ET LEURS
UTILISATIONS**

Patent Applicant/Assignee:

AVENTIS PASTEUR LIMITED, Connaught Campus, 1755 Steeles Avenue West,
Toronto, Ontario M2R 3T4, CA, CA (Residence), CA (Nationality), (For
all designated states except: US)

Patent Applicant/Inventor:

MURDIN Andrew D, 11 Forest Hill Drive, Richmond Hill, Ontario L4B 3C2, CA
, CA (Residence), GB (Nationality), (Designated only for: US)

OOMEN Raymond P, 29 Kennedy St. W., Aurora, Ontario L4G 2L6, CA, CA
(Residence), CA (Nationality), (Designated only for: US)

WANG Joe, 51 Aspen Drive, Toronto, Ontario M2H 2E8, CA, CA (Residence),
CA (Nationality), (Designated only for: US)

DUNN Pamela, 97 Rosebury Lane, Woodbridge, Ontario L4L 3Z1, CA, CA
(Residence), GB (Nationality), (Designated only for: US)

Legal Representative:

NGUYEN Thuy H (et al) (agent), Smart & Biggar, 900-55 Metcalfe Street,
P.O. Box 2999, Station D, Ottawa, Ontario K1P 5Y6, CA,

Patent and Priority Information (Country, Number, Date):

Patent: WO 200175112 A2-A3 20011011 (WO 0175112)

Application: WO 2001CA460 20010404 (PCT/WO CA0100460)

Priority Application: US 2000194472 20000404

Designated States: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU

CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR

KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE

SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

(EP) AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR

(OA) BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

(AP) GH GM KE LS MW MZ SD SL SZ TZ UG ZW

(EA) AM AZ BY KG KZ MD RU TJ TM

Publication Language: English

Filing Language: English

Fulltext Word Count: 18044

Fulltext Availability:

Detailed Description

Detailed Description

... pCACPNM653 containing the glutamate binding protein
gene.

The glutamate binding protein gene was amplified from

Chlamydia pneumoniae genomic DNA strain **CWL029** by polymerase
chain reaction (PCR) using a 51 primer

(51 ATAAGAATGCGGCCGCCACCATGAAGATAAAATTTCTTGAAGG 3'; SEQ ID

No...

1/3,KWIC/8 (Item 4 from file: 349)

DIALOG(R)File 349:PCT FULLTEXT

(c) 2002 WIPO/Univentio. All rts. reserv.

00841550 **Image available**

CHLAMYDIA ANTIGENS AND CORRESPONDING DNA FRAGMENTS AND USES THEREOF

**ANTIGENES DE CHLAMYDIA ET FRAGMENTS D'ADN CORRESPONDANTS, ET UTILISATIONS
DE CEUX-CI**

Patent Applicant/Assignee:

AVENTIS PASTEUR LIMITED, Connaught Campus, 1755 Steeles Avenue West,
Toronto, Ontario M2R 3T4, CA, CA (Residence), CA (Nationality), (For
all designated states except: US)

Patent Applicant/Inventor:

MURDIN Andrew D, 11 Forest Hill Drive, Richmond Hill, Ontario L4B 3C2, CA
, CA (Residence), GB (Nationality), (Designated only for: US)

OOMEN Raymond P, 29 Kennedy St. W., Aurora, Ontario L4G 2L6, CA, CA
(Residence), CA (Nationality), (Designated only for: US)

WANG Joe, 51 Aspen Drive, Toronto, Ontario M2H 2E8, CA, CA (Residence),
CA (Nationality), (Designated only for: US)

DUNN Pamela, 97 Rosebury Lane, Woodbridge, Ontario L4L 3Z1, CA, CA
(Residence), GB (Nationality), (Designated only for: US)

Legal Representative:

NGUYEN Thuy H (et al) (agent), Smart & Biggar, 900-55 Metcalfe Street,
P.O. Box 2999, Station D, Ottawa, Ontario K1P 5Y6, CA,

Patent and Priority Information (Country, Number, Date):

Patent: WO 200175111 A2-A3 20011011 (WO 0175111)
Application: WO 2001CA456 20010404 (PCT/WO CA0100456)
Priority Application: US 2000194471 20000404

Designated States: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU
CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR
KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE
SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW
(EP) AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR
(OA) BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG
(AP) GH GM KE LS MW MZ SD SL SZ TZ UG ZW
(EA) AM AZ BY KG KZ MD RU TJ TM

Publication Language: English

Filing Language: English

Fulltext Word Count: 18039

Fulltext Availability:

Detailed Description

Detailed Description

... pCACPNM760 containing the myosin heavy chain gene.

The myosin heavy chain gene was amplified from

Chlamydia pneumoniae genomic DNA strain **CWL029** by polymerase
chain reaction (PCR) using a 51 primer

(5' ATAAGAATGCGGCCGCCACCATGGCAAATATCCACTAGAGCC 31; SEQ ID

No...

1/3,KWIC/9 (Item 5 from file: 349)

DIALOG(R)File 349:PCT FULLTEXT

(c) 2002 WIPO/Univentio. All rts. reserv.

00841504 **Image available**

CHLAMYDIA ANTIGENS AND CORRESPONDING DNA FRAGMENTS AND USES THEREOF
ANTIGENES DE CHLAMYDIA, FRAGMENTS D'ADN CORRESPONDANTS, ET UTILISATIONS
DESDITS FRAGMENTS

Patent Applicant/Assignee:

AVENTIS PASTEUR LIMITED, Connaught Campus, 1755 Steeles Avenue West,
Toronto, Ontario M2R 3T4, CA, CA (Residence), CA (Nationality), (For
all designated states except: US)

Patent Applicant/Inventor:

MURDIN Andrew D, 11 Forest Hill Drive, Richmond Hill, Ontario L4B 3C2, CA
, CA (Residence), GB (Nationality), (Designated only for: US)

OOMEN Raymond P, 29 Kennedy Street W., Aurora, Ontario L4G 2L6, CA, CA
(Residence), CA (Nationality), (Designated only for: US)

WANG Joe, 51 Aspenwood Drive, Toronto, Ontario M2H 2E8, CA, CA
(Residence), CA (Nationality), (Designated only for: US)

DUNN Pamela, 97 Rosebury Lane, Woodbridge, Ontario L4L 3Z1, CA, CA
(Residence), GB (Nationality), (Designated only for: US)

Legal Representative:

NGUYEN Thuy H (et al) (agent), Smart & Biggar, 900-55 Metcalfe Street,
P.O. Box 2999, Station D, Ottawa, Ontario K1P 5Y6, CA,

Patent and Priority Information (Country, Number, Date):

Patent: WO 200174863 A2-A3 20011011 (WO 0174863)
Application: WO 2001CA455 20010404 (PCT/WO CA0100455)
Priority Application: US 2000194464 20000404

Designated States: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU
CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR
KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE
SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

(EP) AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR

(OA) BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

(AP) GH GM KE LS MW MZ SD SL SZ TZ UG ZW

(EA) AM AZ BY KG KZ MD RU TJ TM

Publication Language: English

Filing Language: English

Fulltext Word Count: 18015

Fulltext Availability:
Detailed Description

Detailed Description

... pCACPNM209 containing the ATP-binding cassette gene.

The ATP-binding cassette gene was amplified from *Chlamydia pneumoniae* genomic DNA strain **CWL029** by polymerase chain reaction (PCR) using a 51 primer
51 ATAAGAATGCGGCCGCCACCATGCGCAAGATATCAGTGGGAATC 3'; SEQ ID
No...

1/3,KWIC/10 (Item 6 from file: 349)
DIALOG(R)File 349:PCT FULLTEXT
(c) 2002 WIPO/Univentio. All rts. reserv.

00812849 **Image available**

CHLAMYDIA ANTIGENS AND CORRESPONDING DNA FRAGMENTS AND USES THEREOF
ANTIGENES DE CHLAMYDIA, FRAGMENTS D'ADN CORRESPONDANTS ET UTILISATIONS DE
CEUX-CI

Patent Applicant/Assignee:

AVENTIS PASTEUR LIMITED, Connaught Campus, 1755 Steeles Avenue West,
Toronto, Ontario M2R 3T4, CA, CA (Residence), CA (Nationality), (For
all designated states except: US)

Patent Applicant/Inventor:

MURDIN Andrew D, 11 Forest Hill Drive, Richmond Hill L4B 3C2, CA, CA
(Residence), GB (Nationality), (Designated only for: US)
OOMEN Raymond P, 29 Kennedy Street W., Aurora, Ontario L4G 2L6, CA, CA
(Residence), CA (Nationality), (Designated only for: US)
WANG Joe, 51 Aspenwood Drive, Toronto, Ontario M2H 2E8, CA, CA
(Residence), CA (Nationality), (Designated only for: US)
DUNN Pamela, 97 Rosebury Lane, Woodbridge, Ontario L4L 3Z1, CA, CA
(Residence), GB (Nationality), (Designated only for: US)

Legal Representative:

MORROW Joy D (et al) (agent), Smart & Biggar, 900-55 Metcalfe Street,
Station D, P.O. Box 2999, Ottawa, Ontario K1P 5Y6, CA,

Patent and Priority Information (Country, Number, Date):

Patent: WO 200146226 A2-A3 20010628 (WO 0146226)
Application: WO 2000CA1536 20001220 (PCT/WO CA0001536)
Priority Application: US 99171538 19991222

Designated States: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ
DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ
LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG
SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW
(EP) AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR
(OA) BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG
(AP) GH GM KE LS MW MZ SD SL SZ TZ UG ZW
(EA) AM AZ BY KG KZ MD RU TJ TM

Publication Language: English

Filing Language: English

Fulltext Word Count: 16495

Fulltext Availability:
Detailed Description

Detailed Description

... plasmid

vector pCABk099 containing the membrane ATPase gene.
The membrane ATPase gene was amplified from *Chlamydia pneumoniae* genomic DNA strain **CWL029** by polymerase chain reaction (PCR) using a 51 primer
(5f ATAAGAATGCGGCCGCCACCATGCAAACAATCTACACAAAAATAAC 3r; SEQ ID
No...

1/3,KWIC/11 (Item 7 from file: 349)
DIALOG(R)File 349:PCT FULLTEXT
(c) 2002 WIPO/Univentio. All rts. reserv.

00812848 **Image available**

CHLAMYDIA ANTIGENS AND CORRESPONDING DNA FRAGMENTS AND USES THEREOF
ANTIGENES ANTI-CHLAMYDIA, FRAGMENTS D'ADN CORRESPONDANTS ET LEURS
UTILISATIONS

Patent Applicant/Assignee:

AVENTIS PASTEUR LIMITED, Connaught Campus, 1755 Steeles Avenue West,
Toronto, Ontario M2R 3T4, CA, CA (Residence), CA (Nationality), (For
all designated states except: US)

Patent Applicant/Inventor:

MURDIN Andrew D, 11 Forest Hill Drive, Richmond Hill, Ontario L4B 3C2, CA
, CA (Residence), GB (Nationality), (Designated only for: US)
OOMEN Raymond P, 29 Kennedy Street West, Aurora, Ontario L4G 2L6, CA, CA
(Residence), CA (Nationality), (Designated only for: US)
WANG Joe, 51 Aspenwood Drive, Toronto, Ontario M2H 2E8, CA, CA
(Residence), CA (Nationality), (Designated only for: US)
DUNN Pamela, 97 Rosebury Lane, Woodbridge, Ontario L4L 3Z1, CA, CA
(Residence), GB (Nationality), (Designated only for: US)

Legal Representative:

MORROW Joy D (et al) (agent), Smart & Biggar, P.O. Box 2999, Station D,
900-55 Metcalfe Street, Ottawa, Ontario K1P 5Y6, CA,

Patent and Priority Information (Country, Number, Date):

Patent: WO 200146225 A2-A3 20010628 (WO 0146225)

Application: WO 2000CA1535 20001220 (PCT/WO CA0001535)

Priority Application: US 99171539 19991222

Designated States: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ
DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ
LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG
SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW
(EP) AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR
(OA) BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG
(AP) GH GM KE LS MW MZ SD SL SZ TZ UG ZW
(EA) AM AZ BY KG KZ MD RU TJ TM

Publication Language: English

Filing Language: English

Fulltext Word Count: 16393

Fulltext Availability:

Detailed Description

Detailed Description

... pCABk319 containing the outer membrane protein gene.

The outer membrane protein gene was amplified from

Chlamydia pneumoniae genomic DNA strain **CWL029** by polymerase
chain reaction (PCR) using a 5' primer

(5f ATAAGAATGCGGCCGCCACCATGAAAAAATTATTATTTTCTAC 3f; SEQ ID

No...

1/3,KWIC/12 (Item 8 from file: 349)

DIALOG(R) File 349:PCT FULLTEXT

(c) 2002 WIPO/Univentio. All rts. reserv.

00810074

COMPLEMENTARY PEPTIDE LIGANDS GENERATED FROM MICROBIAL GENOME SEQUENCES
LIGANDS PEPTIDIQUES COMPLEMENTAIRES PRODUITS A PARTIR DE SEQUENCES
GENOMIQUES MICROBIENNES

Patent Applicant/Assignee:

PROTEOM LIMITED, Babraham Hall, Babraham, Cambridge CB2 4AT, GB, GB
(Residence), GB (Nationality), (For all designated states except: US)

Patent Applicant/Inventor:

ROBERTS Gareth Wyn, The Grange, Church Street, Great Shelford, Cambridge
CB2 5EL, GB, GB (Residence), GB (Nationality), (Designated only for:
US)

HEAL Jonathan Richard, 21 Fingal Street, Greenwich, London SE10 0JL, GB,
GB (Residence), GB (Nationality), (Designated only for: US)

Legal Representative:

DAVIES Jonathan Mark (agent), Reddie & Grose, 16 Theobalds Road, London

WC1X 8PL, GB,
Patent and Priority Information (Country, Number, Date):
Patent: WO 200142278 A2-A3 20010614 (WO 0142278)
Application: WO 2000GB4778 20001213 (PCT/WO GB0004778)
Priority Application: GB 9929466 19991213
Designated States: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ
DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ
LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG
SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW
(EP) AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR
(OA) BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG
(AP) GH GM KE LS MW MZ SD SL SZ TZ UG ZW
(EA) AM AZ BY KG KZ MD RU TJ TM
Publication Language: English
Filing Language: English
Fulltext Word Count: 10697

Fulltext Availability:
Detailed Description

Detailed Description

... et al., Nature,
Genome Size (Mb) 1.44 s/SplashPage.html 390: 580-586 (1997)
Chlamydia pneumoniae CWL029 B Acute respiratory infections and
http:Hchlamydia- Kalman et al., Nat Genome Size (Mb) 1...

1/3,KWIC/13 (Item 9 from file: 349)
DIALOG(R)File 349:PCT FULLTEXT
(c) 2002 WIPO/Univentio. All rts. reserv.

00791380 **Image available**

HIGHLY CONSERVED GENES AND THEIR USE TO GENERATE PROBES AND PRIMERS FOR
DETECTION OF MICROORGANISMS
GENES A FORT POUVOIR DE CONSERVATION ET LEUR UTILISATION POUR PRODUIRE DES
SONDES D'ACIDE NUCLEIQUE SPECIFIQUES A L'ESPECE, SPECIFIQUES AU GENE,
SPECIFIQUES A LA FAMILLE, SPECIFIQUES AU GROUPE ET UNIVERSELLES ET DES
SONDES D'AMPLIFICATION, EN VUE DE DETECTER ET D'IDENTIFIER RAPIDEMENT
DES MICRO-ORGANISMES ALGAIRES, ARCHEOBA

Patent Applicant/Assignee:

INFECTIO DIAGNOSTIC (I D I) INC, 2050 Rene-Levesque Blvd., West, 4th
Floor, Sainte-Foy, Quebec G1V 2K8, CA, CA (Residence), CA (Nationality)
, (For all designated states except: US)

Patent Applicant/Inventor:

BERGERON Michel G, 1145 des Erables, Quebec, Quebec G2K 1T8, CA, CA
(Residence), CA (Nationality), (Designated only for: US)

BOISSINOT Maurice, 109 Jean Bruchesi, St-Augustin-de-Desmaures, Quebec
G3A 2N2, CA, CA (Residence), CA (Nationality), (Designated only for:
US)

HULETSKY Ann, 1231 des Pins Avenue, Sillery, Quebec G1S 4J3, CA, CA
(Residence), CA (Nationality), (Designated only for: US)

MENARD Christian, 1174 du Pont, St-Lambert-de-Levis, Quebec G0S 2W0, CA,
CA (Residence), CA (Nationality), (Designated only for: US)

OUELLETTE Marc, 1035 de Ploermel, Sillery, Quebec G1S 3S1, CA, CA
(Residence), CA (Nationality), (Designated only for: US)

PICARD Francois J, 1245 de la Sapiniere, Cap-Rouge, Quebec G1Y 1A1, CA,
CA (Residence), CA (Nationality), (Designated only for: US)

ROY Paul H, 28 Charles Garnier, Loretteville, Quebec G2A 2X8, CA, CA
(Residence), US (Nationality), (Designated only for: US)

Legal Representative:

DUBUC Jean H (et al) (agent), Goudreau Gage Dubuc, The Stock Exchange
Tower, 800 Place Victoria, Suite 3400, P.O. Box 242, Montreal, Quebec
H4Z 1E9, CA,

Patent and Priority Information (Country, Number, Date):

Patent: WO 200123604 A2-A3 20010405 (WO 0123604)
Application: WO 2000CA1150 20000928 (PCT/WO CA0001150)
Priority Application: CA 2283458 19990928; CA 2307010 20000519

Designated States: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ
DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ

Application: WO 2000EP7548 20000803 (PCT/WO EP0007548)
Priority Application: DE 19936663 19990804; DE 19945175 19990921; DE
19945174 19990921; DE 19948887 19991011; DE 19953309 19991105; DE
10020996 20000428

Designated States: AE AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE
DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK
LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK
SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW
(EP) AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE
(OA) BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG
(AP) GH GM KE LS MW MZ SD SL SZ TZ UG ZW
(EA) AM AZ BY KG KZ MD RU TJ TM

Publication Language: English
Filing Language: English
Fulltext Word Count: 40376

Fulltext Availability:
Detailed Description

Detailed Description

... trachomatis D/UW-3/CX C.T. gb AE00 1 320, 3348-4007 gb AE
Chlamydia pneumoniae CWL029 c. P. gb AE001642, 7155-7790 gb AE
Thermotoga maritima T. M. gb AE001792, 3951...AE000713, 10428-11234
Chlamydia trachomatis D/UW-3/CX C.T. gb AE001352, 9579-10445
Chlamydia pneumoniae CWL029 c. P. gb AE001675, 2514-3406
Thermotoga maritima T. M. gb AE001791.1, 13364-14179...

1/3,KWIC/15 (Item 11 from file: 349)
DIALOG(R)File 349:PCT FULLTEXT
(c) 2002 WIPO/Univentio. All rts. reserv.

00757848

NUCLEIC ACID PROBE-BASED DIAGNOSTIC ASSAYS FOR PROKARYOTIC AND EUKARYOTIC ORGANISMS

DOSAGES DIAGNOSTIQUES D'ACIDES NUCLEIQUES PAR SONDE POUR ORGANISMES PROCARYOTES ET EUCARYOTES

Patent Applicant/Assignee:

ENTERPRISE IRELAND (trading as BioResearch Ireland), Glasnevin, Dublin 9,
IE, IE (Residence), IE (Nationality), (For all designated states
except: US)

NATIONAL UNIVERSITY OF IRELAND GALWAY, University Road, Galway, IE, IE
(Residence), IE (Nationality), (For all designated states except: US)

Patent Applicant/Inventor:

BARRY Thomas Gerard, The Quay, Kinvara, County Galway, IE, IE (Residence)
, IE (Nationality), (Designated only for: US)

SMITH Terence James, 18 Hawthorne Place, Clybaun Road, Galway, IE, IE
(Residence), IE (Nationality), (Designated only for: US)

Legal Representative:

ANNE RYAN & CO (agent), 60 Northumberland Road, Ballsbridge, Dublin 4, IE

Patent and Priority Information (Country, Number, Date):

Patent: WO 200070086 A1 20001123 (WO 0070086)

Application: WO 2000IE66 20000515 (PCT/WO IE0000066)

Priority Application: WO 99IE43 19990514

Designated States: AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE
DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC
LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK
SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW
(EP) AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE
(OA) BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG
(AP) GH GM KE LS MW SD SL SZ TZ UG ZW
(EA) AM AZ BY KG KZ MD RU TJ TM

Publication Language: English
Filing Language: English
Fulltext Word Count: 23736

Fulltext Availability:
Detailed Description

Claims

Detailed Description

... ID NO: 159

Bordetella bronchiseptica tmRNA

GGGGCCGAUCCGGAUUCGACGUGGGUCAUGAAACAGCUCAAGGC
20 AUGCCGAGCACCAGUAAGCUCGUTJAAUCCACUGGAACACUACAA
ACGCCAACGACGAGCGUUUCGCUCUCGCCGCUAAGCGGUGAGC
CGCUGCACUGAUCUGUCCUUGGGUCACGCGGGGGAA

SEQ ID NO: 160

Chlamydiapneumoniae (CWL029), ssrA

GGGGGTGTATAGGTTTCGACTTGAAAATGAAGTGTTAATTGCAT
GCGGAGGGCGTTGGCTGGCCTCCTAAAAAGCCAACAAAACAATA
AATGCCGAACCTAAGGCTGAATGCGAAATTATTAGCTTGTTTGA
CTCAGTAGAGGAAAGACTAGCTGCTTAATTAGCAAAAGTTGTTA
GCTAGATAATCTCTAGGTAACCCGGTATCTGCGAGCTCCACCAG
AGGCTTGCAAAATACCGTCATTTATCTGGTTGGAACCTACTTTCT
CTAATTCTCAAGGAAGTTCGTTTCGAGATTTTGGAGAGTCATTGGC
TGCTATAGAGGCTTCTAGCTAAGGGAGTCCAATGTAAACAATTTC
10 TAGAAGATAAGCATGTAGAGGTTAGCAGGGAGTTTGTCAAGGAC
GAGAGTTCGAGTCTCTCCACCTCCACCA SEQ ID NO: 161

Chlamydiapneumoniae (CWL029) tmRNA

GGGGGUGUAUAGGUUUCGACUUGAAAAUGAAGUGUUAUUGC
15 AUGCGGAGGGCGUUGGCUGGCCUCCUAAAAAGCCAACAAAACA
AUAAUAGCCGAACCUAAGGCUGAAUGCGAAUUAUAGCUUG
UUUGACUCAGUAGAGGAAAGACUAGCUGCUUAAUAGCAAAA
GUUGUAGCUAGAUAAUCUCUAGGUAACCCGGUAUCUGCGAG
CUCCACCAGAGGCUUGCAAAAUACCGUCAUUUAUCUGGUUGGA
20 ACUUACUUUCUCUAAUUCUCAAGGAAGUUCGUUCGAGAUUUU
UGAGAGUCAUUGGCUGCUAUAGAGGCUUCUAGCUAAGGGAGU
CCAAUGUAAACAAUUCUAGAAGAUAGCAUGUAGAGGUUAGC
AGGGAGUUUGUCAAGGACGAGAGUUCGAGUCUCUCCACCUCCA
CCA SEQ...

Claim

... ucucgccgcu 120

uaagcgguga gccgcugcac ugaucugucc uugggucacg cgggggaa 168

<210> 161

<211> 426

<212> DNA

<213> *Chlamydia pneumoniae* (CWL029)

<400> 161

gggggtgtat aggtttcgac ttgaaaatga agtggttaatt gcatgaggag ggcgttggct 60
ggcctcctaa aaagccaaca aaacaataaa tgccgaacct aaggctgaat gcgaaattat...
agaggtagc agggagtttg tcaaggacga gaggtagc cttccacct 420
ccacca 426

<210> 162

<211> 426

<212> RNA

<213> *Chlamydia pneumoniae* (CWL029)

<400> 162

ggggguguaa agguuucgac uugaaaauga aguguaauu gcaugcggag gqcgauugcu 60
ggccuccuaa aaagccaaca aaacaauaaa ugccgaaccu aaggcugaau gcgaaauau...

1/3,KWIC/16 (Item 12 from file: 349)

DIALOG(R)File 349:PCT FULLTEXT

(c) 2002 WIPO/Univentio. All rts. reserv.

00733372

MEDICAMENT

MEDICAMENT

Patent Applicant/Assignee:

NEUTEC PHARMA PLC, St. James's Court, Brown Street, Manchester, Cheshire
M2 2JF, GB, GB (Residence), GB (Nationality), (For all designated
states except: US)

Patent Applicant/Inventor:

BURNIE James Peter, 1 Greystoke Drive, Alderley Edge, Cheshire SK9 7PY,
GB, GB (Residence), GB (Nationality), (Designated only for: US)

MATTHEWS Ruth Christine, 1 Greystoke Drive, Alderley Edge, Cheshire SK9
7PY, GB, GB (Residence), GB (Nationality), (Designated only for: US)

Legal Representative:

MCNEIGHT & LAWRENCE, Regent House, Heaton Lane, Stockport, Cheshire SK4
1BS, GB

Patent and Priority Information (Country, Number, Date):

Patent: WO 200046359 A2 20000810 (WO 0046359)

Application: WO 2000GB237 20000128 (PCT/WO GB0000237)

Priority Application: GB 992555 19990205

Designated States: AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK

DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR

LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ

TM TR TT TZ UA UG US UZ VN YU ZA ZW

(EP) AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

(OA) BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

(AP) GH GM KE LS MW SD SL SZ TZ UG ZW

(EA) AM AZ BY KG KZ MD RU TJ TM

Publication Language: English

Filing Language: English

Fulltext Word Count: 7984

Fulltext Availability:

Detailed Description

Detailed Description

... the present invention and the amino acid
sequence it encodes are already known from the **Chlamydia** Genome Project
(*C. pneumoniae* **CWL029** /CPn0809), as is an apparent *C. trachomatis*
homologue (CT578). However, therapeutic and diagnostic uses for...
?logoff hold

10oct02 14:57:56 User228206 Session D1873.4

\$0.01 0.002 DialUnits File155

\$0.01 Estimated cost File155

\$1.80 0.378 DialUnits File349

\$19.20 12 Type(s) in Format 3

\$19.20 12 Types

\$21.00 Estimated cost File349

\$0.01 0.002 DialUnits File5

\$0.01 Estimated cost File5

\$0.02 0.002 DialUnits File73

\$0.02 Estimated cost File73

OneSearch, 4 files, 0.384 DialUnits FileOS

\$0.21 TELNET

\$21.25 Estimated cost this search

\$21.25 Estimated total session cost 0.384 DialUnits

RESULT 2

AAY34620

ID AAY34620 standard; Protein; 348 AA.

XX AC AAY34620;

XX DT 13-SEP-1999 (first entry)

XX DE Chlamydia pneumoniae lipoprotein sequence.

XX KW Respiratory disease; pneumonia; bronchitis; heart disease; sarcoidosis;
KW sinusitis; purulent otitis media; erythema nodosum; pharyngitis;
XX vaccine; neutralising epitope.

OS Chlamydia pneumoniae.

XX PN WO9927105-A2.

XX PD 03-JUN-1999.

XX PF 20-NOV-1998; 98WO-IB01890.

XX PR 04-NOV-1998; 98US-0107078.

XX PR 21-NOV-1997; 97FR-0014673.

XX PA (GEST) GENSET.

XX PI Griffais R;

XX DR WPI; 1999-357842/30.

XX PT Genome sequence of Chlamydia pneumoniae

XX PS Page 640; Disclosure; 1912pp; English.

XX CC AAY34584-Y35879 represent the proteins encoded by all the open reading
CC frames in the complete genome (see AAX91990) of Chlamydia pneumoniae.
CC C. pneumoniae causes respiratory disease such as pneumonia and
CC bronchitis and is thought to be a contributing factor in heart
CC disease, sarcoidosis, sinusitis, purulent otitis media, erythema
CC nodosum or pharyngitis. The polypeptides encoded by the open reading
CC frames of the C. pneumoniae genome (see AAY34584-Y35879) can be used in
CC immunogenic compositions as vaccines. Vectors containing C. pneumoniae
CC nucleotides sequences can also be used as immunogenic compositions,
CC especially where the vector directs the expression of a neutralising
CC epitope of C. pneumoniae.

XX SQ Sequence 348 AA;

Query Match 57.6%; Score 327; DB 20; Length 348;
Best Local Similarity 100.0%; Pred. No. 6.7e-302;
Matches 327; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MGLFHLTLFGLLLCSLPISLVAKFPESVGHKILYISTQSTQOALATYLEALDAYGDHDF 60
Db 21 mglfhltlfglllclslpislvakfpesvghkilyistqstqqalatylealdagdhdf 80
QY 61 VLRKIGEDYLKQSIHSSDPQTRKSTIIGAGLAGSSEALDVLVSQAMETADPLQQLLVLSAV 120
Db 81 vlrkigedylkqsihssdpqtrkstiigaglagsssealdvlsqametadplqqlvlvsav 140
QY 121 SGHLGKTSDDLKALASPPYVIRLEAAYRLANLKNKVIDHLHSFIHKLPEEIQLSAA 180
Db 141 sghlgktsddlkalasppvirleaayrlanlknkvidhlhsfihklpeeiclsaa 200
QY 181 IFLRLETEESDAYIRDLLAAKKSAIRSATALQIGEYQQRFLPTLRNLLTSASPDQGEAI 240
Db 201 iflrleteesdayirdllaakksairsatalqigeyqqkrflptlrnlltsaspdqgeai 260
QY 241 LYALGKLDGQSYNNIKKQLQKPDVDVTLAAQALIALGKEEDALPVKKQALEERPRAL 300
Db 261 lyalgkldgqsyynikkqlqkpdvdtlaaaqalialgkeedalpvikqaleerpral 320
QY 301 YALRHLPSEIGIPIALPIFLKTKNSEA 327
Db 321 yalrhlpseigipialpiflktknsea 347

RESULT 3

il6.411:DIALINDEX(R)

DIALINDEX(R)

(c) 2002 The Dialog Corporation plc

*** DIALINDEX search results display in an abbreviated ***

*** format unless you enter the SET DETAIL ON command. ***

?sf allscience

You have 278 files in your file list.

(To see banners, use SHOW FILES command)

?s chlamyd?/ti and vaccin?/ti

Your SELECT statement is:

s chlamyd?/ti and vaccin?/ti

Items	File
84	5: Biosis Previews(R)_1969-2002/Oct W1
1	6: NTIS_1964-2002/Oct W2
8	9: Business & Industry(R)_Jul/1994-2002/Oct 14
38	10: AGRICOLA_70-2002/Oct
38	16: Gale Group PROMT(R)_1990-2002/Oct 14
7	18: Gale Group F&S Index(R)_1988-2002/Oct 14
2	19: Chem.Industry Notes_1974-2002/ISS 200242
10	20: Dialog Global Reporter_1997-2002/Oct 15
59	34: SciSearch(R) Cited Ref Sci_1990-2002/Oct W2
4	35: Dissertation Abs Online_1861-2002/Sep
6	42: Pharmaceuticl News Idx_1974-2002/Oct W1
78	50: CAB Abstracts_1972-2002/Sep
30	65: Inside Conferences_1993-2002/Oct W2
21	71: ELSEVIER BIOBASE_1994-2002/Oct W1
56	73: EMBASE_1974-2002/Oct W1
1	74: Int.Pharm.Abs._1970-2002/Sep
3	98: General Sci Abs/Full-Text_1984-2002/Sep
3	99: Wilson Appl. Sci & Tech Abs_1983-2002/Sep

Examined 50 files

>>>Term "TI" is not defined in file 107 and is ignored

13	107: Adis R&D Insight_1986-2002/Oct W1
11	111: TGG Natl.Newspaper Index(SM)_1979-2002/Oct 11

>>>Term "TI" is not defined in file 115 and is ignored

4	115: Research Centers & Services_1994-2002/Jul
---	--

>>>Term "TI" is not defined in file 124 and is ignored

1	124: CLAIMS/REFERENCE 2001/2002Q1
---	-----------------------------------

>>>Term "TI" is not defined in file 128 and is ignored

19	128: PHARMAPROJECTS_1980-2002/Oct W1
10	129: PHIND(Archival)_1980-2002/Oct W1
2	135: NewsRx Weekly Reports_1995-2002/Oct W1
12	143: Biol. & Agric. Index_1983-2002/Sep
50	144: Pascal_1973-2002/Oct W2
13	148: Gale Group Trade & Industry DB_1976-2002/Oct 15
7	149: TGG Health&Wellness DB(SM)_1976-2002/Oct W1
74	155: MEDLINE(R)_1966-2002/Oct W1
3	156: ToxFile_1965-2002/Oct W2
3	160: Gale Group PROMT(R)_1972-1989
11	162: CAB Health_1983-2002/Sep

>>>Term "TI" is not defined in file 167 and is ignored

1	167: Medical Device Register (R)_1999
1	172: EMBASE Alert_2002/Oct W2
1	174: Pharm-line(R)_1978-2002/Oct W1
3	180: Federal Register_1985-2002/Oct 11
2	185: Zoological Record Online(R)_1978-2002/Sep

>>>Term "TI" is not defined in file 189 and is ignored

13	189: NDA Pipeline: New Drugs_1991-2002/Aug
24	203: AGRIS_1974-2002/May

Examined 100 files

4	266: FEDRIP_2002/Jul
9	285: BioBusiness(R)_1985-1998/Aug W1

>>>Term "TI" is not defined in file 286 and is ignored

36	286: Biocommerce Abs.& Dir._1981-2002/Sep B2
----	--

2 315: ChemEng & Biotec Abs_1970-2002/Sep
 6 319: Chem Bus NewsBase_1984-2002/Oct 15
 18 340: CLAIMS(R)/US Patent_1950-02/Oct 10
 47 342: Derwent Patents Citation Indx_1978-01/200225
 4 344: Chinese Patents Abs_Aug 1985-2002/Oct
 39 345: Inpadoc/Fam.& Legal Stat_1968-2002/UD=200240
 1 347: JAPIO_Oct 1976-2002/Jun(Updated 021004)
 17 348: EUROPEAN PATENTS_1978-2002/Oct W01
 18 349: PCT FULLTEXT_1979-2002/UB=20021010,UT=20021003
 96 357: Derwent Biotech Res._1982-2002/JUNE W1

Examined 150 files

2 358: Current BioTech Abs_1983-2002/Sep
 1 369: New Scientist_1994-2002/Sep W3
 1 371: French Patents_1961-2002/BOPI 200209
 >>>Term "TI" is not defined in file 375 and is ignored
 1 375: Derwent Drug Registry_1997-2002/Sep W4
 >>>Term "TI" is not defined in file 390 and is ignored
 40 390: Beilstein Online
 61 399: CA SEARCH(R)_1967-2002/UD=13716
 2 429: Adis Newsletters(Archive)_1982-2002/Oct 15
 24 434: SciSearch(R) Cited Ref Sci_1974-1989/Dec
 983 440: Current Contents Search(R)_1990-2002/Oct 14
 5 441: ESPICOM Pharm&Med DEVICE NEWS_2002/Oct W2
 14 445: IMS R&D Focus_1991-2002/Oct W1
 >>>Term "TI" is not defined in file 453 and is ignored
 6 453: Drugs of the Future_1990-2002/Aug
 6 455: Drug News & Perspectives_1992-2002/Sep
 8 459: Daily Essentials (Archival)_1996-2002/Sep W4
 2 484: Periodical Abs Plustext_1986-2002/Oct W1

Examined 200 files

>>>Term "TI" is not defined in file 590 and is ignored
 1 590: KOMPASS Western Europe_2002/FEB
 2 610: Business Wire_1999-2002/Oct 15
 3 613: PR Newswire_1999-2002/Oct 15
 8 621: Gale Group New Prod.Annou.(R)_1985-2002/Oct 11
 1 635: Business Dateline(R)_1985-2002/Oct 12
 29 636: Gale Group Newsletter DB(TM)_1987-2002/Oct 14
 1 637: Journal of Commerce_1986-2002/Oct 10
 9 649: Gale Group Newswire ASAP(TM)_2002/Oct 10
 15 654: US PAT.FULL._1976-2002/Oct 08

Examined 250 files

3 761: Datamonitor Market Res._1992-2002/Oct
 1 764: BCC Market Research_1989-2002/Oct
 1 765: Frost & Sullivan_1992-1999/Apr
 5 767: Frost & Sullivan Market Eng_2002/Sep
 1 810: Business Wire_1986-1999/Feb 28
 4 813: PR Newswire_1987-1999/Apr 30

83 files have one or more items; file list includes 278 files.
 One or more terms were invalid in 90 files.

?save temp

Temp SearchSave "TD611" stored

?rf

Your last SELECT statement was:

S CHLAMYD?/TI AND VACCIN?/TI

R

SYSTEM:OS - DIALOG OneSearch

File 155:MEDLINE(R) 1966-2002/Oct W1

*File 155: Alert feature enhanced for multiple files, duplicates removal, customized scheduling. See HELP ALERT.

File 10:AGRICOLA 70-2002/Oct

(c) format only 2002 The Dialog Corporation

File 65:Inside Conferences 1993-2002/Oct W2

(c) 2002 BLDSC all rts. reserv.

File 203:AGRIS 1974-2002/May

Dist by NAL, Intl Copr. All rights reserved

File 636:Gale Group Newsletter DB(TM) 1987-2002/Oct 14

(c) 2002 The Gale Group

File 654:US PAT.FULL. 1976-2002/Oct 08

(c) FORMAT ONLY 2002 THE DIALOG CORP.

*File 654: is redesigned with new search and display features. See HELP NEWS654 for details. Reassignments current through Jun. 7, 2002.

File 348:EUROPEAN PATENTS 1978-2002/Oct W01

(c) 2002 European Patent Office

File 35:Dissertation Abs Online 1861-2002/Sep

(c) 2002 ProQuest Info&Learning

File 344:Chinese Patents Abs Aug 1985-2002/Oct

(c) 2002 European Patent Office

File 347:JAPIO Oct 1976-2002/Jun(Updated 021004)

(c) 2002 JPO & JAPIO

*File 347: JAPIO data problems with year 2000 records are now fixed.

Alerts have been run. See HELP NEWS 347 for details.

File 371:French Patents 1961-2002/BOPI 200209

(c) 2002 INPI. All rts. reserv.

*File 371: This file is not currently updating. The last update is 200209.

Set Items Description

--- ----

Cost is in DialUnits

?t s2/9/1 2 3 5 6 8 11 12 15 16 19 36 37

2/9/1 (Item 1 from file: 155)

DIALOG(R)File 155:MEDLINE(R)

13556958 22051209 PMID: 12056482

Protection evaluation against Chlamydomphila abortus challenge by DNA vaccination with a dnaK-encoding plasmid in pregnant and non-pregnant mice.

Hechard Celine; Grepinet Olivier; Rodolakis Annie

Unite de Pathologie Infectieuse et Immunologie, INRA. Centre de Tours, Nouzilly, France.

Veterinary research (France) May-Jun 2002, 33 (3) p313-26, ISSN

0928-4249 Journal Code: 9309551

Document type: Evaluation Studies; Journal Article

Languages: ENGLISH

Main Citation Owner: NLM

Record type: Completed

Subfile: INDEX MEDICUS

Mice were intramuscularly immunized with a dnaK-encoding DNA plasmid. The protective effect of DNA immunization against Chlamydomphila abortus infection was studied in pregnant and non-pregnant mice models. In non-pregnant mice, the dnaK vaccine induced a specific humoral response with the predominant IgG2a isotype, which failed to have in vitro neutralizing properties. No delayed-type hypersensitivity reaction was observed and the spleens of dnaK vaccinated-mice were not protected against C. abortus challenge. In pregnant mice, the dnaK vaccine induced a non-specific partial protection from abortion. This may be due to the immunogenic properties of the CpG motifs of bacterial DNA present in the vaccinal plasmid backbone. Nevertheless, spleens of dnaK vaccinated-pregnant mice were not protected.

Tags: Animal; Female; Pregnancy; Support, Non-U.S. Gov't

Descriptors: *Chlamydomphila--immunology--IM; *Chlamydomphila Infections --veterinary--VE; *Heat-Shock Proteins 70--genetics--GE; *Vaccines, DNA --administration and dosage--AD; Antibodies, Bacterial--biosynthesis--BI;

Chlamydomophila--genetics--GE; Chlamydomophila Infections --prevention and control--PC; Disease Models, Animal; Heat-Shock Proteins 70--immunology--IM; Immunoglobulin G--biosynthesis--BI; Immunoglobulin G--blood--BL; Injections, Intramuscular--veterinary--VE; Mice; Plasmids; Recombinant Proteins--genetics--GE; Recombinant Proteins--immunology--IM; Spleen --immunology--IM; Spleen--microbiology--MI; Vaccines, DNA--immunology--IM
CAS Registry No.: 0 (Antibodies, Bacterial); 0 (Heat-Shock Proteins 70); 0 (Immunoglobulin G); 0 (Plasmids); 0 (Recombinant Proteins); 0 (Vaccines, DNA); 0 (dnaK protein)
Record Date Created: 20020611

2/9/2 (Item 2 from file: 155)
DIALOG(R) File 155:MEDLINE(R)

13493579 21906483 PMID: 11908999

Chlamydia vaccines : strategies and status.

Igietsme Joseph U; Black Carolyn M; Caldwell Harlan D

Microbiology & Immunology, Morehouse School of Medicine, 720 Westview Drive SW, Atlanta, Georgia 30310, USA. igietsj@msm.edu

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy (New Zealand) 2002, 16 (1) p19-35, ISSN 1173-8804

Journal Code: 9705305

Contract/Grant No.: AI 41231; AI; NIAID; GM 08248; GM; NIGMS; RR 03034; RR; NCRR

Document type: Journal Article; Review; Review, Tutorial

Languages: ENGLISH

Main Citation Owner: NLM

Record type: Completed

Subfile: INDEX MEDICUS

The ultimate goal of current chlamydial vaccine efforts is to utilise either conventional or modern vaccinology approaches to produce a suitable immunisation regimen capable of inducing a sterilising, long-lived heterotypic protective immunity at mucosal sites of infection to curb the severe morbidity and worldwide prevalence of chlamydial infections. This lofty goal poses tremendous challenges that include the need to clearly define the relevant effectors mediating immunity, the antigens responsible for inducing these effectors, the anti-chlamydial action(s) of effectors, and establishment of the most effective method of vaccine delivery. Tackling these challenges is further compounded by the biological complexity of chlamydia, the existence of multiple serovariants, the capacity to induce both protective and deleterious immune effectors, and the occurrence of asymptomatic and persistent infections. Thus, novel molecular, immunological and genetic approaches are urgently needed to extend the frontiers of current knowledge, and develop new paradigms to guide the production of an effective vaccine regimen. Progress made in the last 15 years has culminated in various paradigm shifts in the approaches to designing chlamydial vaccines. The dawn of the current immunological paradigm for antichlamydial vaccine design has its antecedence in the recognition that chlamydial immunity is mediated primarily by a T helper type1 (Th1) response, requiring the induction and recruitment of specific T cells into the mucosal microenvironment. Additionally, the ancillary role of humoral immune response in complementing the Th1-driven protective immunity, through ensuring adequate memory and optimal Th1 response during a reinfection, has been recognised. With continued progress in chlamydial genomics and proteomics, select chlamydial proteins, including structural, membrane and secretory proteins, are being targeted as potential subunit vaccine candidates. However, the development of an effective adjuvant, delivery vehicle or system for a potential subunit vaccine is still an elusive objective in these efforts. Promising delivery vehicles include DNA and virus vectors, bacterial ghosts and dendritic cells. Finally, a vaccine still represents the best approach to protect the greatest number of people against the ocular, pulmonary and genital diseases caused by chlamydial infections. Therefore, considering the urgency and the enormity of these challenges, a **partially** protective vaccine preventing certain severe sequelae would constitute an acceptable short-term goal to control Chlamydia. However, more research efforts and support are needed to achieve the worthy goal of protecting a significant number of the world's population from the devastating consequences of chlamydial invasion of the

Languages: ENGLISH

Main Citation Owner: NLM

Record type: Completed

Subfile: INDEX MEDICUS

Chlamydia pneumoniae is an intracellularly growing bacterium that causes respiratory infections and is strongly associated with atherosclerosis. Antibodies against C. pneumoniae are frequently encountered in the adult population, indicating past exposure to the micro-organism. Immunity to reinfection is, however, only **partial** and does not prevent development of sequelae. Infections caused by and associated with C. pneumoniae are a major cause of morbidity and mortality world wide. Development of a vaccine capable of protecting against infections due to C. pneumoniae and their sequelae would prevent up to 10% of community-acquired pneumonias in adults and add a new dimension to the prevention of atherosclerosis and coronary heart disease. (64 Refs.)

Tags: Human; Support, Non-U.S. Gov't

Descriptors: *Bacterial Vaccines; *Chlamydia Infections--prevention and control--PC; *Chlamydia pneumoniae--immunology--IM; Adult; Arteriosclerosis--microbiology--MI; Arteriosclerosis --prevention and control--PC; Chlamydia Infections--immunology--IM; Coronary Disease --microbiology--MI; Coronary Disease--prevention and control--PC; Respiratory Tract Infections--microbiology--MI; Respiratory Tract Infections--prevention and control--PC

CAS Registry No.: 0 (Bacterial Vaccines)

Record Date Created: 20000211

2/9/6 (Item 6 from file: 155)

DIALOG(R) File 155:MEDLINE(R)

10203051 99171732 PMID: 10073724

Vaccination of mice with DNA plasmids coding for the Chlamydia trachomatis major outer membrane protein elicits an immune response but fails to protect against a genital challenge.

Pal S; Barnhart K M; Wei Q; Abai A M; Peterson E M; de la Maza L M

Department of Pathology, Medical Sciences I, University of California, Irvine 92697-4800, USA.

Vaccine (ENGLAND) Feb 5 1999, 17 (5) p459-65, ISSN 0264-410X

Journal Code: 8406899

Contract/Grant No.: AI-30499; AI; NIAID; AI-32248; AI; NIAID

Document type: Journal Article

Languages: ENGLISH

Main Citation Owner: NLM

Record type: Completed

Subfile: INDEX MEDICUS

A DNA plasmid encoding the gene of the major outer membrane protein (MOMP) of the Chlamydia trachomatis mouse pneumonitis (MoPn) serovar and three plasmids containing the variable domains (VD) of the MOMP were constructed. Female mice were inoculated with the plasmids and 60 days later were challenged in the genital tract with C. trachomatis. Six weeks after challenge female mice were caged with male mice and the course of the mating followed. Mice immunized with the MOMP plasmids mounted weak humoral and cell mediated immune responses. However, following the genital challenge no significant differences in vaginal shedding were observed between the groups immunized with the MOMP and control plasmids. In addition, the fertility rates were similar in the experimental and negative control groups. In conclusion, vaccination with DNA plasmids encoding the MOMP elicited a modest immune response but did not protect against infection or disease.

Tags: Animal; Female; Male; Pregnancy; Support, U.S. Gov't, P.H.S.

Descriptors: *Bacterial Outer Membrane Proteins--immunology--IM; *Bacterial Vaccines--immunology--IM; *Chlamydia Infections--prevention and control--PC; *Chlamydia trachomatis--immunology--IM; *Genital Diseases, Female--prevention and control--PC; *Plasmids--immunology--IM; *Vaccines, DNA--immunology--IM; Antibodies, Bacterial--blood--BL; Bacterial Outer Membrane Proteins--genetics--GE; Genetic Vectors; Mice; Mice, Inbred Strains; Vaccination

CAS Registry No.: 0 (Antibodies, Bacterial); 0 (Bacterial Outer Membrane Proteins); 0 (Bacterial Vaccines); 0 (Genetic Vectors); 0

human mucosal epithelia. (210 Refs.)

Tags: Animal; Human; Support, Non-U.S. Gov't; Support, U.S. Gov't, P.H.S.
Descriptors: *Bacterial Vaccines--therapeutic use--TU; *Chlamydia
--immunology--IM; *Chlamydia Infections--drug therapy--DT; *Chlamydia
Infections--prevention and control--PC; *Technology, Pharmaceutical--trends
--TD; Bacterial Vaccines--administration and dosage--AD; Bacterial
Vaccines--chemical synthesis--CS; Bacterial Vaccines--immunology--IM;
Chlamydia Infections--immunology--IM; Drug Delivery Systems--methods--MT;
Drug Delivery Systems--trends--TD; Technology, Pharmaceutical--methods--MT
CAS Registry No.: 0 (Bacterial Vaccines)
Record Date Created: 20020322

2/9/3 (Item 3 from file: 155)

DIALOG(R) File 155:MEDLINE(R)

11035453 20580045 PMID: 11137265

**Immunity to Chlamydia pneumoniae induced by vaccination with DNA
vectors expressing a cytoplasmic protein (Hsp60) or outer membrane proteins
(MOMP and Omp2).**

Penttila T; Vuola J M; Puurula V; Anttila M; Sarvas M; Rautonen N; Makela
P H; Puolakkainen M

Department of Virology, POB 21, Haartman Institute, University of
Helsinki, FIN-00014, Helsinki, Finland. tulla.penttila@helsinki.fi

Vaccine (ENGLAND) Dec 8 2000, 19 (9-10) p1256-65, ISSN 0264-410X
Journal Code: 8406899

Document type: Journal Article

Languages: ENGLISH

Main Citation Owner: NLM

Record type: Completed

Subfile: INDEX MEDICUS

Immune responses induced by intramuscular DNA immunization with Chlamydia
pneumoniae genes coding for the major outer membrane protein (MOMP),
cysteine-rich outer membrane protein 2 (Omp2) or the heat shock protein 60
(Hsp60) were studied. BALB/c mice were vaccinated intramuscularly three
times at 3-week intervals and challenged intranasally 2 weeks after the
last injection. Immunization with pmomp or phsp60 showed 1.2-1.5 log
reduction in the mean lung bacterial counts after the challenge. Specific
antibodies were detected only in sera of the mice immunized with pomp2 and
phsp60. Although immunization with pomp2 resulted in a strong serum
antibody response against Omp2 protein, it **failed** to protect the mice.
Immunization with any of the three vaccines did not reduce the severity of
histologically assessed pneumonia, but resulted in significantly higher
lymphoid reaction in the lung indicating immunological memory.

Tags: Animal; Female; Support, Non-U.S. Gov't

Descriptors: *Bacterial Outer Membrane Proteins--genetics--GE; *Bacterial
Vaccines--immunology--IM; *Chaperonin 60--genetics--GE; *Chlamydia
pneumoniae--immunology--IM; *Vaccines, DNA--immunology--IM; Antibodies,
Bacterial--blood--BL; Bacterial Outer Membrane Proteins--immunology--IM;
COS Cells; Chaperonin 60--immunology--IM; Lymphocyte Transformation; Mice;
Mice, Inbred BALB C; Vaccination

CAS Registry No.: 0 (Antibodies, Bacterial); 0 (Bacterial Outer
Membrane Proteins); 0 (Bacterial Vaccines); 0 (Chaperonin 60); 0
(Vaccines, DNA); 0 (major outer membrane protein, C. pneumoniae)

Record Date Created: 20010118

2/9/5 (Item 5 from file: 155)

DIALOG(R) File 155:MEDLINE(R)

10573200 20111561 PMID: 10646092

Vaccination against infections by Chlamydia pneumoniae.

Puolakkainen M; Makela P H

Haartman Institute, Department of Virology, University of Helsinki,
Finland. mirja.puolakkainen@helsinki.fi

Comptes rendus de l'Academie des sciences. Serie III, Sciences de la vie
(FRANCE) Nov 1999, 322 (11) p973-8, ISSN 0764-4469 Journal Code:
8503078

Document type: Journal Article; Review; Review, Tutorial

File 440:Current Contents Search(R) 1990-2002/Oct 10
(c) 2002 Inst for Sci Info
File 345:Inpadoc/Fam.& Legal Stat 1968-2002/UD=200239
(c) 2002 EPO

Set	Items	Description
S1	5	AU=GRIFFAIS ? (100N) CHLAMYD?
?t s1/3/5		

1/3/5 (Item 2 from file: 345)
DIALOG(R) File 345:Inpadoc/Fam.& Legal Stat
(c) 2002 EPO. All rts. reserv.

CHLAMYDIA PNEUMONIAE GENOMIC SEQUENCE AND POLYPEPTIDES, FRAGMENTS THEREOF
AND USES THEREOF, IN PARTICULAR FOR THE DIAGNOSIS, PREVENTION AND
TREATMENT OF INFECTION (English; French)

Author (Inventor): GRIFFAIS REMY (FR); ZAGURSKY ROBERT J (US); METCALF BENJAMIN J (US); PEEK JOEL A (US); SANKARAN BANUMATHI (US); HOISETH SUSAN K (US); FLETCHER LEAH D (US)

Patent Family:

Patent No	Kind	Date	Applic No	Kind	Date	
AU 9911702	A1	19990615	AU 9911702	A	19981120	
BR 9814878	A	20001003	BR 98U14878	A	19981120	
CA 2307846	AA	19990603	CA 2307846	A	19981120	(BASIC)
CN 1279717	T	20010110	CN 98811378	A	19981120	
EP 1032674	A2	20000906	EP 98954662	A	19981120	
WO 9927105	A2	19990603	WO 98IB1890	A	19981120	
WO 9927105	A3	19991111	WO 98IB1890	A	19981120	

FR 9714673 A 19971121
WO 98IB1890 W 19981120
US 107078 P 19981104

\$12.03	Estimated total session cost	0.161	DialUnits
---------	------------------------------	-------	-----------

U

[illegible]

(Plasmids); 0 (Vaccines, DNA); 146409-23-6 (major outer membrane protein, Chlamydia trachomatis)

Record Date Created: 19990507

2/9/8 (Item 8 from file: 155)

DIALOG(R) File 155:MEDLINE(R)

08733973 96088055 PMID: 8525685

Protective efficacy of a parenterally administered MOMP-derived synthetic oligopeptide vaccine in a murine model of Chlamydia trachomatis genital tract infection: serum neutralizing IgG antibodies do not protect against chlamydial genital tract infection.

Su H; Parnell M; Caldwell H D

Laboratory of Intracellular Parasites, NIAID, Rocky Mountain Laboratories, Hamilton, MT 59840, USA.

Vaccine (ENGLAND) Aug 1995, 13 (11) p1023-32, ISSN 0264-410X

Journal Code: 8406899

Document type: Journal Article

Languages: ENGLISH

Main Citation Owner: NLM

Record type: Completed

Subfile: INDEX MEDICUS

The protective efficacy of an alum-adsorbed, parenterally administered synthetic oligopeptide immunogen corresponding to antigenically common T-helper and neutralizing B-cell epitopes of the Chlamydia trachomatis major outer membrane protein was studied in a murine model of chlamydial genital tract infection. Mice produced high levels of anti-chlamydial serum IgG neutralizing antibodies following subcutaneous immunization with the alum-adsorbed oligopeptide. Lower but detectable levels of chlamydial specific IgG antibodies were found in vaginal washes. IgG1 was the predominant isotype present in sera and vaginal washes. Chlamydial-specific IgA was not present in either the sera or vaginal washes of immunized mice. Vaccinated and control mice were challenged intravaginally or intrauterinally with low, medium, or high doses of C. trachomatis serovar D challenge inocula. Protection was assessed by performing quantitative chlamydial cervico-vaginal cultures over the course of the infection period. There were no statistically significant differences between groups of immunized and control mice in either colonization, shedding, or duration of infection. These findings demonstrate that parenteral immunization with the oligopeptide (serum-neutralizing antibodies) is **ineffective** in preventing chlamydial genital tract infection. It is possible, since chlamydial infection is restricted to the genital tract mucosae, that a more accurate evaluation of the oligopeptide vaccine potential will require local rather than systemic immunization.

Tags: Animal; Female

Descriptors: *Antibodies, Bacterial--biosynthesis--BI; *Bacterial Outer Membrane Proteins--immunology--IM; *Bacterial Vaccines--immunology--IM; *Chlamydia Infections--prevention and control--PC; *Chlamydia trachomatis--immunology--IM; *Immunoglobulin G--blood--BL; *Vaccines, Synthetic--immunology--IM; *Vaginal Diseases--prevention and control--PC; Administration, Intravaginal; Antibodies, Bacterial--blood--BL; Bacterial Vaccines--administration and dosage--AD; Chlamydia Infections--blood--BL; Immunoglobulin G--biosynthesis--BI; Immunoglobulin Isotypes--analysis--AN; Immunoglobulin Isotypes--blood--BL; Injections, Subcutaneous; Mice; Mice, Inbred A; Neutralization Tests; Oligopeptides--immunology--IM; Uterus; Vaccines, Synthetic--administration and dosage--AD; Vagina--immunology--IM; Vaginal Diseases--blood--BL

CAS Registry No.: 0 (Antibodies, Bacterial); 0 (Bacterial Outer Membrane Proteins); 0 (Bacterial Vaccines); 0 (Immunoglobulin G); 0 (Immunoglobulin Isotypes); 0 (Oligopeptides); 0 (Vaccines, Synthetic); 146409-23-6 (major outer membrane protein, Chlamydia trachomatis)

Record Date Created: 19960125

2/9/11 (Item 11 from file: 155)

DIALOG(R) File 155:MEDLINE(R)

07238784 92180061 PMID: 1796460

The problems of vaccination against chlamydial abortion sheep]
Zur Problematik der Vakzination gegen den **Chlamydienabort** beim Schaf.

Thiele D

Institut für Hygiene und Infektionskrankheiten der Tiere,
Justus-Liebig-Universität Giessen.

Tierärztliche Praxis (GERMANY) Dec 1991, 19 (6) p605-7, ISSN
0303-6286 Journal Code: 7501042

Document type: Journal Article; Review; Review, Tutorial ; English
Abstract

Languages: GERMAN

Main Citation Owner: NLM

Record type: Completed

Subfile: INDEX MEDICUS

Different vaccines used against chlamydial abortion in sheep are described. Problems associated with insufficient immunity after vaccination are discussed. Reasons for **failure** of certain vaccine preparations are addressed. Finally new developments in vaccine production are introduced which might be useful in solving problems still existing in the prevention of chlamydial abortion in sheep by vaccination. (24 Refs.)

Tags: Animal; Female; Pregnancy

Descriptors: *Abortion, Veterinary--prevention and control--PC;
*Bacterial Vaccines; *Chlamydia Infections--veterinary--VE; *Sheep Diseases
--prevention and control--PC; *Vaccination--veterinary--VE; Chlamydia
--immunology--IM; Chlamydia Infections--prevention and control--PC; Sheep

CAS Registry No.: 0 (Bacterial Vaccines)

Record Date Created: 19920406

2/9/12 (Item 12 from file: 155)

DIALOG(R) File 155:MEDLINE(R)

06463504 90170744 PMID: 2407704

Efficacy of a vaccine to prevent Chlamydia - or Campylobacter-induced abortions in ewes.

Hansen D E; Hedstrom O R; Sonn R J; Snyder S P

College of Veterinary Medicine, Oregon State University, Corvallis
97331-4802.

Journal of the American Veterinary Medical Association (UNITED STATES)
Mar 1 1990, 196 (5) p731-4, ISSN 0003-1488 Journal Code: 7503067

Document type: Journal Article

Languages: ENGLISH

Main Citation Owner: NLM

Record type: Completed

Subfile: INDEX MEDICUS

In a sheep flock, Chlamydia psittaci, Campylobacter fetus, Ca jejuni, and Salmonella dublin caused abortions. A vaccine that contained C psittaci type I from 2 sources: a cow with pneumonia and an aborted ovine fetus, Ca fetus, Ca jejuni, and 4 strains of K99 Escherichia coli was given to 240 ewes before they were bred. All fetuses, placentas, and lambs, that **died** within 36 hours of birth were examined for infectious agents. Of 55 abortions, 30 (55%) were caused by Chlamydia or Campylobacter spp; 25 of the 30 (83%) abortions took place in the nonvaccinated group (n = 240). Forty-five more lambs **survived** in the vaccinated group than in the nonvaccinated group. Abortion rates for Chlamydia and Campylobacter spp (2.1 vs 10.4% in vaccinated and nonvaccinated groups, respectively) were significantly different (P = 0.003). Abortion rates for S dublin were not significantly different between groups. The Salmonella epizootic was controlled quickly by sanitation and treatment procedures. The vaccine was at least 80% efficacious against Chlamydia and Campylobacter spp and appeared to be protective.

Tags: Animal; Female; Pregnancy

Descriptors: *Abortion, Veterinary--prevention and control--PC;
*Bacterial Vaccines; *Campylobacter Infections--veterinary--VE; *Ornithosis
--veterinary--VE; *Sheep Diseases--prevention and control--PC;
Campylobacter Infections--prevention and control--PC; Campylobacter fetus
--immunology--IM; Chlamydia psittaci--immunology--IM; Escherichia coli
--immunology--IM; Ornithosis--prevention and control--PC; Sheep;
Vaccination--veterinary--VE

CAS Registry No.: 0 (Bacterial Vaccines)

2/9/15 (Item 1 from file: 65)

DIALOG(R)File 65:Inside Conferences

(c) 2002 BLDSC all rts. reserv. All rts. reserv.

03011062 INSIDE CONFERENCE ITEM ID: CN031896828

Detection of Cd4+ T-Cells in the Genital Tract of Mice Vaccinated with Formulated RMOMP that Confers Partial Protection Against Chlamydial Infertility

Maisonneuve, J.; Charlier, C.; Friede, M.; Abarca-Quinones, J.
CONFERENCE: European Society for Chlamydia Research-Meeting; 3rd
PROCEEDINGS-EUROPEAN SOCIETY FOR CHLAMYDIA RESEARCH, 1996; NO 3 P: 473
Uppsala, ESCR, 1996

LANGUAGE: English DOCUMENT TYPE: Conference Extended abstracts

CONFERENCE EDITOR(S): Stary, A.

CONFERENCE SPONSOR: European Society for Chlamydia Research
Austrian Society for Dermatology and Venerology Study Group
for STD and Dermatological Microbiology

CONFERENCE LOCATION: Vienna

CONFERENCE DATE: Sep 1996 (199609) (199609)

BRITISH LIBRARY ITEM LOCATION: 6699.453000

DESCRIPTORS: ESCR; chlamydia research; dermatological microbiology

2/9/16 (Item 2 from file: 65)

DIALOG(R)File 65:Inside Conferences

(c) 2002 BLDSC all rts. reserv. All rts. reserv.

01962028 INSIDE CONFERENCE ITEM ID: CN020438360

Intramuscular Immunization with a DNA Vaccine Produces Partial Immunity to Chlamydia trachomatis Infection

Zhang, D.-J.; Yang, X.; Shen, C.; Berry, J.

CONFERENCE: Modern approaches to the control of infectious diseases-
Annual meeting; 14th

VACCINES, 1997 P: 113-118

Cold Spring Harbor Laboratory Press, 1997

ISSN: 0899-4056 ISBN: 0879695161

LANGUAGE: English DOCUMENT TYPE: Conference Papers

CONFERENCE EDITOR(S): Brown, F.

CONFERENCE LOCATION: Cold Spring Harbor, NY

CONFERENCE DATE: Sep 1996 (199609) (199609)

BRITISH LIBRARY ITEM LOCATION: 9138.650000

NOTE:

Also known as Vaccines 97

DESCRIPTORS: infectious diseases; vaccines

2/9/19 (Item 3 from file: 636)

DIALOG(R)File 636:Gale Group Newsletter DB(TM)

(c) 2002 The Gale Group. All rts. reserv.

03983264 Supplier Number: 53053370 (THIS IS THE FULLTEXT)

Chlamydia Vaccine Nose Is Best Site for Chlamydia Vaccine .
Vaccine Weekly, pNA

Sept 28, 1998

ISSN: 1074-2921

Language: English Record Type: Fulltext

Document Type: Newsletter; Trade

Word Count: 502

TEXT:

The path to a chlamydia vaccine goes through the nose.

Animal studies show that Chlamydia trachomatis antigens administered by the intranasal route elicit the kind of immunity known to protect against chlamydia infection and disease.

"Intranasal immunization is a potential delivery route of choice in

the development of a vaccine against Chlamydia," concluded Joseph U. Igietseme of Morehouse School of Medicine, Atlanta, Georgia, and colleagues.

Igietseme et al. reported their findings in the journal Infection and Immunity ("Route of Infection that Induces a High Intensity of Gamma Interferon-Secreting T Cells in the Genital Tract Produces Optimal Protection against Chlamydia trachomatis Infection in Mice," Infect Immun, 1998;66(9):4030-5).

Chlamydia trachomatis is a sexually transmitted bacterial infection. **Failure** to diagnose and treat the insidious infection, which can remain asymptomatic for long periods of time, can result in pelvic inflammatory disease, ectopic pregnancy, and/or infertility. There are 4 million cases in the U.S. each year, representing yearly health-care costs of \$2.18 billion.

Igietseme et al. noted that a number of animal studies show that immune control of C. trachomatis infection requires T-cell mediated immune responses involving interferon gamma.

They hypothesized that vaccine elicitation of interferon gamma secreting T lymphocytes (ISTLs) in the genital tract would differ depending upon the route of vaccine administration.

The researchers used C. trachomatis elementary bodies (EBs) as a crude vaccine antigen for immunization of female BALB/c mice. They administered the antigen either intranasally, intravaginally, orally, or subcutaneously.

T-cells obtained from the animals' genital tracts were restimulated with chlamydial antigen in vitro and analyzed.

"The results suggested that immunization routes that foster rapid induction of vigorous genital mucosal cell-mediated immune (CMI) effectors (e.g., interferon gamma), the CMI-associated humoral effector, IgG2a, and to some extent secretory IgA produce immunity against chlamydial genital infection," Igietseme et al. reported.

One question unanswered by the study is whether chlamydial immunity induced by intranasal immunization can be long lasting.

"Of particular importance to chlamydial genital infection are the factors that regulate the persistence of immune effectors at the genital mucosal site and so foster long-term genital mucosal immunity," Igietseme et al. wrote. "The natures of such factors are presently unknown, but they will be important for the persistence of ISTLs in the genital mucosae."

The researchers currently are hoping to back-engineer a vaccine antigen by cloning interferon-secreting T lymphocytes from the genital tracts of intranasally immunized mice. It is hoped that these clones may help find the crucial protective chlamydial epitopes.

"The identification, mapping, and characterization of such protective epitopes may furnish valuable reagents for designing an experimental vaccine against Chlamydia," Igietseme et al. suggested.

This study was supported by Public Health Service grants AI41231 and RR03034 from the National Institutes of Health.

The corresponding author for this study is Joseph U. Igietseme, Morehouse School of Medicine, Department of Microbiology and Immunology, 720 Westview Dr., SW, Atlanta, GA 30310. Phone: (404) 752-1596. Fax: (404) 752-1179. Email: less than igietsj@msm.edu greater than .

- by Daniel J. DeNoon, Senior Editor

THIS IS THE FULL TEXT: COPYRIGHT 1998 Charles W Henderson Subscription: \$1468 per year as of 1/97. Published 52 times per year. Contact Charles W Henderson, P.O. Box 5528, Atlanta, GA 31107-0528. Phone 404-377-8895. Fax 404-378-4511.

COPYRIGHT 1999 Gale Group

PUBLISHER NAME: Charles W. Henderson

EVENT NAMES: *310 (Science & research)

GEOGRAPHIC NAMES: *1USA (United States)

PRODUCT NAMES: *2831210 (Vaccines for Human Use)

INDUSTRY NAMES: BUSN (Any type of business); HLTH (Healthcare - Medical and Health)

NAICS CODES: 325412 (Pharmaceutical Preparation Manufacturing)

2/9/36 (Item 1 from file: 35)

DIALOG(R) File 35:Dissertation Abs Online

(c) 2002 ProQuest Info&Learning. All rts. reserv.

01743207 ORDER NO: AADAA-I9970077

Development of immune responses in mice to *Chlamydia pneumoniae* induced by intramuscular genetic vaccination

Author: Tharp, Anthony C.

Degree: Ph.D.

Year: 2000

Corporate Source/Institution: Vanderbilt University (0242)

Director: William M. Mitchell

Source: VOLUME 61/04-B OF DISSERTATION ABSTRACTS INTERNATIONAL.

PAGE 1889. 89 PAGES

Descriptors: HEALTH SCIENCES, PATHOLOGY ; HEALTH SCIENCES, IMMUNOLOGY

Descriptor Codes: 0571; 0982

ISBN: 0-599-75065-0

Chlamydia pneumoniae, formerly known as TWAR, is a common respiratory tract pathogen which has been associated with 10 percent of diagnosed pneumoniae cases (1). Moreover, world-wide population studies have shown that *C. pneumoniae* is ubiquitous and that re-infection is common (1). Recently, seroepidemiological and ultrastructural studies have associated this pathogen with atherosclerotic cardiovascular disease (2). Atherosclerosis and its complications (i.e., myocardial infarct, ischemic heart disease, and stroke) account for more than 50 percent of deaths in the United States (3). Evidence of *C. pneumoniae* being a risk factor was documented during a five-year follow-up of patients being treated for coronary heart disease (CHD). This study documented elevated sera IgA titers against *C. pneumoniae* lipopolysaccharide (LPS) that correlated with an increased risk for CHD (4). Evidence for *C. pneumoniae*'s role in acute myocardial infarcts was documented with 57 percent of these patients having circulating immune complexes containing Chlamydial antigen (LPS) as compared to 12 percent of controls (5).

Although standard antimicrobial therapy is believed to be effective, *C. pneumoniae* infections are usually silent or mildly symptomatic, and therefore not treated, leading to a chronic, persistent infection (6). No studies have been reported that specifically target chronic *C. pneumoniae* for antibiotic eradication. Excessive costs of antibiotic treatment, the necessity of testing large populations, and the potential for drug-resistant strains to develop with therapy are potential problems with treating this pathogen. However, the potential costs of leaving the organism untreated if leading to atherosclerosis is also enormous. Although there is not an effective vaccine currently, one may be designed to offer protection. In this thesis the hypothesis that genetic DNA vaccination in the mouse model using the major outer membrane protein (MOMP) of *C. pneumoniae* as the cellular expressed antigen, will result in an effective vaccine. Genetic vaccination using a plasmid containing MOMP will be tested with a comparison between unmodulated DNA, enhancement by the method of Hormone Immunomodulated Genetic Vaccination (HIGV), and recombinant MOMP for protective efficacy. Systemic humoral and cellular responses to the vaccine will be measured and correlated with protective efficacy.

2/9/37 (Item 2 from file: 35)

DIALOG(R)File 35:Dissertation Abs Online

(c) 2002 ProQuest Info&Learning. All rts. reserv.

01404150 ORDER NO: AADAA-I9510389

EXPRESSION OF THE CHLAMYDIA PSITTACI MAJOR OUTER MEMBRANE PROTEIN IN ESCHERICHIA COLI: A MODEL FOR TRANSLOCATION AND VACCINE DEVELOPMENT

Author: DASCHER, CHRISTOPHER CARTER

Degree: PH.D.

Year: 1994

Corporate Source/Institution: THE UNIVERSITY OF ROCHESTER (0188)

Supervisor: PATRIK BAVOIL

Source: VOLUME 55/11-B OF DISSERTATION ABSTRACTS INTERNATIONAL.

PAGE 4693. 193 PAGES

Descriptors: BIOLOGY, MICROBIOLOGY

Descriptor Codes: 0410

Chlamydia infections represent a serious ongoing health problem throughout the world. The major outer membrane protein (MOMP) of Chlamydia species is an abundant component of the chlamydial outer membrane and is the target of neutralizing antibodies in infected individuals. The entire omp1 gene encoding MOMP from Chlamydia psittaci strain GPIC has been cloned and expressed in Escherichia coli. A tightly regulated T7 promoter is used to control expression of the protein in E. coli. Upon induction of expression, the precursor MOMP (pre-MOMP) is synthesized in the cell. This is followed by the appearance of a lower molecular weight protein that comigrates with mature MOMP from chlamydial elementary bodies on both one-dimensional SDS-PAGE and two-dimensional gels. MOMP is not detected in surface labeling experiments using several MOMP-specific antibodies. In addition, MOMP expressed in E. coli is not accessible to protease treatment without prior permeabilization of the outer membrane. These data indicate that pre-MOMP is translocated to the periplasmic space and processed but is not surface-exposed in E. coli.

Biochemical and genetic techniques have been used to characterize the chlamydial homolog of Hsp60. Coexpression in E. coli of MOMP or a MOMP-PhoA fusion with Hsp60, or other chaperones, does not alter the level of MOMP translocation. The Hsp60 protein from C. psittaci was purified from isolated organisms. Hsp60 was investigated for the presence of intermolecular complexes with translocated chlamydial proteins. Chlamydial Hsp60 can function in trans to suppress a lethal temperature sensitive mutation of a cytoplasmic protein in E. coli.

Highly purified recombinant MOMP and Omp2, another cysteine-rich chlamydial outer membrane protein, were generated. These proteins were used in immunological studies of protective chlamydial antigens. Only MOMP could prime a protective antibody response in BALB/c mice. C3H/HeJ mice, a strain non-responsive to MOMP, failed to elicit protective antibodies using various combinations of recombinant MOMP and Omp2 as immunogens. An attenuated Salmonella typhimurium strain was used to deliver both MOMP and Omp2 by oral immunization but was unsuccessful in eliciting anti chlamydial antibodies.

?t s2/3,kwic/31 32

2/3,KWIC/31 (Item 9 from file: 654)
DIALOG(R)File 654:US PAT.FULL.
(c) FORMAT ONLY 2002 THE DIALOG CORP. All rts. reserv.

3230019 **IMAGE Available
Derwent Accession: 1991-245693

Utility

C/ Nucleotide, deduced amino acid sequence, isolation and purification of heat-shock chlamydial proteins; DETECTION; VACCINE AGAINST CHLAMYDIA INFECTION

Inventor: Morrison, Richard P., Hamilton, MT
Caldwell, Harlan D., Hamilton, MT

Assignee: The United State of America as represented by the Department of Health and Human Services (06), Washington, DC
U S of America Health & Human Services (Code: 06814)

Examiner: Moskowitz, Margaret (Art Unit: 186)

Assistant Examiner: Cunningham, Thomas

Law Firm: Cushman, Darby & Cushman

	Publication Number	Kind	Date	Application Number	Filing Date
Main Patent	US 5071962	A	19911210	US 90531317	19900531
Priority				US 90531317	19900531

Nucleotide, deduced amino acid sequence, isolation and purification of heat-shock chlamydial proteins

Description of the Invention:

...C. psittaci (GPIC) genomic DNA isolated from 6X10¹⁰ IFU, was partially digested with Sau3A, and sized by electrophoresis on a 0.7% agarose gel (Nano, et...

...50 kD, presumably a truncated version of the 57-kD protein found in

pGP57. A **partial** sequence of the 2.0-kb chlamydial DNA fragment from the E1 subclone was obtained...the manufacturer's suggested procedures (Sequenase, United States Biochemical Corp., Cleveland, Ohio). After obtaining a **partial** DNA sequence from the E1 subclone, sequencing was continued using synthetic oligonucleotide primers (SAM1, Milligen... immune guinea pigs (Watkins, supra). Since a major genus-specific constituent of this extract (LPS) **failed** to induce ocular hypersensitivity, the extract was purified using immunoaffinity chromatography to obtain the 45...organisms, lanes 1 and 5, and the recombinant HypB proteins, lanes 2 and 4, but **failed** to react with the homologous protein found in E. coli. (lane 3...

2/3,KWIC/32 (Item 10 from file: 654)

DIALOG(R) File 654:US PAT.FULL.

(c) FORMAT ONLY 2002 THE DIALOG CORP. All rts. reserv.

2422624

Derwent Accession: 1982-41396E

Utility

EXPIRED

C/ Vaccine **against** chlamydous infections of farm animals; INACTIV ED
SUSPENS ION OF CELLS OF EGG YOLKS

Inventor: Kurbanov, Ildus A., Nauchny gorodok, 1, kv. 6, Kazan, SU
Jusupov, Rasikh K., Nauchny gorodok, 1, kv. 35, Kazan, SU
Borovik, Roman V., ulitsa Lunacharskogo, 37, kv. 9, Serpukhov, Moskovskaya oblast, SU
Gabdulkhaev, Talgat G., Nauchny gorodok, 2, kv. 11, Kazan, SU
Kurbanova, Ilmira A., ulitsa Sibirsky trakt, 8, kv. 47, Kazan, SU

Assignee: Unassigned

UNASSIGNED OR ASSIGNED TO INDIVIDUAL (Code: 68000)

Examiner: Rose, Shep K. (Art Unit: 125)

Law Firm: Burgess, Ryan and Wayne

	Publication Number	Kind	Date	Application Number	Filing Date
Main Patent	US 4328208	A	19820504	US 81265559	19810520
Priority				US 81265559	19810520

Vaccine **against** chlamydous infections of farm animals...

Description of the Invention:

...3) of the animals are not vaccinated. The control non-vaccinated animals (white mice) have **died**, while pregnant guinea pigs have aborted. The vaccinated white mice **survive**, while vaccinated pregnant guinea pigs give healthy brood...vaccinated heifers after the infection have aborted or brough before time weak, nonvital calves which **died** within three days after calving. In all of them the delay in afterbirth emission...

?logoff hold

15oct02 08:23:17 User228206 Session D1874.5

\$0.33 0.104 DialUnits File155

\$1.68 8 Type(s) in Format 9

\$1.68 8 Types

\$2.01 Estimated cost File155

\$0.02 0.009 DialUnits File10

\$0.02 Estimated cost File10

\$0.20 0.052 DialUnits File65

\$2.20 2 Type(s) in Format 9

\$2.20 2 Types

\$2.40 Estimated cost File65

\$0.02 0.009 DialUnits File203

\$0.02 Estimated cost File203

\$0.14 0.026 DialUnits File636

\$3.45 1 Type(s) in Format 9

\$3.45 1 Types

\$3.59 Estimated cost File636

\$1.23 0.208 DialUnits File654
 \$1.40 2 Type(s) in Format 3
 \$1.40 2 Types
 \$2.63 Estimated cost File654
 \$0.04 0.009 DialUnits File348
 \$0.04 Estimated cost File348
 \$0.14 0.035 DialUnits File35
 \$4.60 2 Type(s) in Format 9
 \$4.60 2 Types
 \$4.74 Estimated cost File35
 \$0.09 0.009 DialUnits File344
 \$0.09 Estimated cost File344
 \$0.10 0.009 DialUnits File347
 \$0.10 Estimated cost File347
 \$0.04 0.009 DialUnits File371
 \$0.04 Estimated cost File371
 OneSearch, 11 files, 0.477 DialUnits FileOS
 \$0.21 TELNET
 \$15.89 Estimated cost this search
 \$15.89 Estimated total session cost 0.477 DialUnits

Status: Signed Off. (1 minutes)

le 369:New Scientist 1994-2002/Sep W2

(c) 2002 Reed Business Information Ltd.

File 370:Science 1996-1999/Jul W3

(c) 1999 AAAS

*File 370: This file is closed (no updates). Use File 47 for more current information.

File 399:CA SEARCH(R) 1967-2002/UD=13715

(c) 2002 American Chemical Society

*File 399: Use is subject to the terms of your user/customer agreement.

Alert feature enhanced for multiple files, etc. See HELP ALERT.

File 434:SciSearch(R) Cited Ref Sci 1974-1989/Dec

(c) 1998 Inst for Sci Info

File 442:AMA Journals 1982-2002/Sep B2

(c) 2002 Amer Med Assn -FARS/DARS apply

*File 442: UDs have been adjusted to reflect the current months' data.

No data is missing.

File 444:New England Journal of Med. 1985-2002/Oct W2

(c) 2002 Mass. Med. Soc.

File 467:ExtraMED(tm) 2000/Dec

(c) 2001 Informania Ltd.

*File 467: For information about updating status please see Help News467.

Set Items Description

--- ----

Cost is in DialUnits

?ds

Set	Items	Description
S1	24	CWL029 (10N) CHLAMYDI?
S2	16	RD (unique items)
S3	0	AU=GRIFFALIS ? AND CHLAMYD?
S4	0	AU=GRIFFALIS ? AND CHLAMYD?
S5	27	AU=GRIFFAIS ? AND CHLAMYD?
S6	2	S5/1999:2002
S7	25	S5 NOT S6

?t s7/9/1-5

7/9/1 (Item 1 from file: 155)

DIALOG(R) File 155:MEDLINE(R)

09173308 97075916 PMID: 8918239

Choosing highly specific primers for the polymerase chain reaction using the octomer frequency disparity method: application to Chlamydia trachomatis.

Chenal V; Souque P; Markovits A; Griffais R

Laboratoire des Rickettsiales et des Chlamydiales, Institut Pasteur, Paris, France.

Gene (NETHERLANDS) Oct 17 1996, 176 (1-2) p97-101, ISSN 0378-1119

Journal Code: 7706761

Document type: Journal Article

Languages: ENGLISH

Main Citation Owner: NLM

Record type: Completed

Subfile: INDEX MEDICUS

The eight-nucleotide sequence (octomer) at the 3' end of PCR primers is important to PCR specificity. We describe a correlation between the specificity of PCR primers used with human DNA and the frequency of the 3' octomer in a human database. We therefore applied a methodology (OFD) based on octomer frequency disparity to identify 16 PCR targets in the chromosome of the intracellular bacterium, *Chlamydia trachomatis* (Ct). In addition, the 16 sets of primers were tested with a standard procedure. All the primer pairs were highly specific for Ct and did not lead to non-specific amplification when used with human DNA. This work shows that the choice of specific PCR primers is possible using a method based on the statistical representativeness of octomers in genomes.

Tags: Human

Descriptors: *Chlamydia trachomatis*--genetics--GE; *DNA Primers;

*Polymerase Chain Reaction; Chromosomes, Bacterial; Oligodeoxyribonucleotides; Sensitivity and Specificity

CAS Registry No.: 0 (DNA Primers); 0 (Oligodeoxyribonucleotides)
Record Date Created: 19970107

7/9/2 (Item 2 from file: 155)
DIALOG(R) File 155:MEDLINE(R)

08576774 95336475 PMID: 7612032

Amplification of plasmid and chromosome Chlamydia DNA in synovial fluid of patients with reactive arthritis and undifferentiated seronegative oligoarthropathies.

Bas S; Griffais R; Kvien T K; Glennas A; Melby K; Vischer T L
Research Laboratory, University Hospital, Geneva, Switzerland.

Arthritis and rheumatism (UNITED STATES) Jul 1995, 38 (7) p1005-13,
ISSN 0004-3591 Journal Code: 0370605

Document type: Journal Article

Languages: ENGLISH

Main Citation Owner: NLM

Record type: Completed

Subfile: AIM; INDEX MEDICUS

OBJECTIVE. To investigate the hypothesis that whole bacteria might be found in the joints of patients with **Chlamydia** -associated reactive arthritis. METHODS. The presence of 2 plasmid- and 2 chromosome-specific sequences of **Chlamydia** DNA was investigated by amplification with the polymerase chain reaction, in synovial fluid (SF) samples from 71 patients with various arthropathies. RESULTS. **Chlamydia** DNA was found in SF samples from 22 patients. CONCLUSION. Whole **chlamydiae** are likely present in the SF of patients with **Chlamydia** -associated reactive arthritis.

Tags: Female; Human; Male

Descriptors: Arthritis, Reactive--microbiology--MI; * **Chlamydia** --genetics--GE; * **Chlamydia** Infections--microbiology--MI; *DNA, Bacterial --analysis--AN; *Synovial Fluid--microbiology--MI; Adolescence; Adult; Base Sequence; Blotting, Southern; **Chlamydia** --isolation and purification--IP; Chromosomes, Bacterial--chemistry--CH; DNA, Bacterial--chemistry--CH; DNA, Bacterial--genetics--GE; Gene Amplification; Middle Age; Molecular Sequence Data; Plasmids--genetics--GE; Polymerase Chain Reaction; Sensitivity and Specificity

CAS Registry No.: 0 (DNA, Bacterial); 0 (Plasmids)

Record Date Created: 19950814

7/9/3 (Item 3 from file: 155)
DIALOG(R) File 155:MEDLINE(R)

06667492 90364279 PMID: 2168087

Synthesis of digoxigenin-labelled DNA probe by polymerase chain reaction: application to Epstein-Barr virus and Chlamydia trachomatis.

Griffais R; Andre P M; Thibon M

Laboratoire des Chlamydiales et Rickettsiales, Institut Pasteur, Paris, France.

Research in virology (FRANCE) May-Jun 1990, 141 (3) p331-5, ISSN 0923-2516 Journal Code: 8907469

Document type: Journal Article

Languages: ENGLISH

Main Citation Owner: NLM

Record type: Completed

Subfile: INDEX MEDICUS

Descriptors: **Chlamydia** trachomatis--genetics--GE; *DNA Probes --biosynthesis--BI; *Digoxigenin; *Digoxin; *Herpesvirus 4, Human--genetics --GE; Blotting, Southern; DNA, Bacterial--analysis--AN; DNA, Viral --analysis--AN; Digoxin--analogs and derivatives--AA; Polymerase Chain Reaction

CAS Registry No.: 0 (DNA Probes); 0 (DNA, Bacterial); 0 (DNA, Viral); 1672-46-4 (Digoxigenin); 20830-75-5 (Digoxin)

Record Date Created: 19901004

7/9/4 (Item 4 from file: 155)
DIALOG(R) File 155:MEDLINE(R)

SYSTEM:OS - DIALOG OneSearch

File 440:Current Contents Search(R) 1990-2002/Oct 10
(c) 2002 Inst for Sci Info

File 345:Inpadoc/Fam.& Legal Stat 1968-2002/UD=200239
(c) 2002 EPO

Set Items Description

Cost is in DialUnits
?ds

Set Items Description
S1 5 AU=GRIFFAIS ? (100N) CHLAMYD?
?t s1/3/5

1/3/5 (Item 2 from file: 345)

DIALOG(R)File 345:Inpadoc/Fam.& Legal Stat
(c) 2002 EPO. All rts. reserv.

15163549

Basic Patent (No,Kind,Date): CA 2307846 AA 19990603 <No. of Patents: 007>
CHLAMYDIA PNEUMONIAE GENOMIC SEQUENCE AND POLYPEPTIDES, FRAGMENTS THEREOF

AND USES THEREOF, IN PARTICULAR FOR THE DIAGNOSIS, PREVENTION AND
TREATMENT OF INFECTION (English; French)

Patent Assignee: GENSET SA (FR)

Author (Inventor): GRIFFAIS REMY (FR); ZAGURSKY ROBERT J (US); METCALF
BENJAMIN J (US); PEEK JOEL A (US); SANKARAN BANUMATHI (US); HOISETH
SUSAN K (US); FLETCHER LEAH D (US)

IPC: *C12N-015/31; C07K-019/00; A01K-067/027; A61K-039/118; C07K-016/12;
C07K-014/295; G01N-033/53; C12N-015/62; C12Q-001/68

CA Abstract No: *131(03)028638M;
Derwent WPI Acc No: *C 99-357842;

Language of Document: English

Patent Family:

Patent No	Kind	Date	Applic No	Kind	Date
AU 9911702	A1	19990615	AU 9911702	A	19981120
BR 9814878	A	20001003	BR 98U14878	A	19981120
CA 2307846	AA	19990603	CA 2307846	A	19981120 (BASIC)
CN 1279717	T	20010110	CN 98811378	A	19981120
EP 1032674	A2	20000906	EP 98954662	A	19981120
WO 9927105	A2	19990603	WO 98IB1890	A	19981120
WO 9927105	A3	19991111	WO 98IB1890	A	19981120

Priority Data (No,Kind,Date):

FR 9714673 A 19971121

WO 98IB1890 W 19981120

US 107078 P 19981104

?logoff hold

06322703 90018831 PMID: 2678327

Detection of Chlamydia trachomatis by the polymerase chain reaction.

Griffais R ; Thibon M

Laboratoire des Chlamydiales et Rickettsiales, Institut Pasteur, Paris.

Research in microbiology (FRANCE) Feb 1989, 140 (2) p139-41, ISSN

0923-2508 Journal Code: 8907468

Document type: Journal Article

Languages: ENGLISH

Main Citation Owner: NLM

Record type: Completed

Subfile: INDEX MEDICUS

Tags: Comparative Study; Human

Descriptors: Chlamydia trachomatis--isolation and purification--IP;

Bacteriological Techniques; Chlamydia Infections--diagnosis--DI;

Chlamydia trachomatis--genetics--GE; Fluorescent Antibody Technique;

Polymerase Chain Reaction

Record Date Created: 19891030

7/9/5 (Item 1 from file: 349)

DIALOG(R) File 349: PCT FULLTEXT

(c) 2002 WIPO/Univentio. All rts. reserv.

00183025

IMPROVEMENTS RELATED TO TECHNIQUES FOR THE AMPLIFICATION OF NUCLEIC ACID
PERFECTIONNEMENTS APPORTES AUX TECHNIQUES D'AMPLIFICATION D'ACIDE NUCLEIQUE

Patent Applicant/Assignee:

INSTITUT PASTEUR,

GRIFFAIS Remy,

Inventor(s):

GRIFFAIS Remy

Patent and Priority Information (Country, Number, Date):

Patent: WO 9100363 A1 19910110

Application: WO 90FR499 19900703 (PCT/WO FR9000499)

Priority Application: FR 898873 19890703

Designated States: AU BG CA HU JP KR RO SU US

Main International Patent Class: C12Q-001/68

International Patent Class: C12Q-01:48; C12Q-01:70; C07H-21:04

Publication Language: French

Fulltext Word Count: 6460

English Abstract

Improvement relating to techniques for the amplification of nucleic acids, in particular by polymerization chain reaction (PCR). Said process for the detection and/or the identification of a nucleic acid sequence or of a mixture of nucleic acid sequences once the biological sample has been placed in an appropriate solution in order to extract the nucleic acid or acids, includes the following steps: (1) the destruction of the 5' ends of the nucleic acid sequences with double strand which are present in the sample, by bringing said biological sample into contact with an appropriate reaction agent which is active at a temperature of between 37degrees - 42degreesC; (2) the actual amplification by bringing the resulting sample into contact with (1) appropriate reagents, in particular amplification initiators suitable for the amplification of the target sequence or sequences to be detected, in the presence of a heat-resistant polymerase DNA; (3) detection of the specific amplified target sequences.

AAY34619
 ID AAY34619 standard; Protein; 245 AA.
 XX
 AC AAY34619;
 XX
 DT 13-SEP-1999 (first entry)
 XX
 DE Chlamydia pneumoniae transmembrane protein sequence.
 XX
 KW Respiratory disease; pneumonia; bronchitis; heart disease; sarcoidosis;
 KW sinusitis; purulent otitis media; erythema nodosum; pharyngitis;
 KW vaccine; neutralising epitope.
 XX
 OS Chlamydia pneumoniae.
 XX
 PN WO9927105-A2.
 XX
 PD 03-JUN-1999.
 XX
 PF 20-NOV-1998; 98WO-IB01890.
 XX
 PR 04-NOV-1998; 98US-0107078.
 PR 21-NOV-1997; 97FR-0014673.
 XX
 PA (GEST) GENSET.
 XX
 PI Griffais R;
 XX
 DR WPI; 1999-357842/30.
 XX
 PT Genome sequence of Chlamydia pneumoniae
 XX
 PS Page 639-640; Disclosure; 1912pp; English.
 XX
 CC AAY34584-Y35879 represent the proteins encoded by all the open reading
 CC frames in the complete genome (see AAX91990) of Chlamydia pneumoniae.
 CC C. pneumoniae causes respiratory disease such as pneumonia and
 CC bronchitis and is thought to be a contributing factor in heart
 CC disease, sarcoidosis, sinusitis, purulent otitis media, erythema
 CC nodosum or pharyngitis. The polypeptides encoded by the open reading
 CC frames of the C. pneumoniae genome (see AAY34584-Y35879) can be used in
 CC immunogenic compositions as vaccines. Vectors containing C. pneumoniae
 CC nucleotides sequences can also be used as immunogenic compositions,
 CC especially where the vector directs the expression of a neutralising
 CC epitope of C. pneumoniae.
 XX
 SQ Sequence 245 AA;

Query Match 42.4%; Score 241; DB 20; Length 245;
 Best Local Similarity 100.0%; Pred. No. 2.3e-220;
 Matches 241; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 328 KLNVALALLELGCDTPKLLLEYITERLVQPHYNETLALSFSKGRTLQNWKRNVIIIVPQDPQ 387
 Db 5 klnvalallelgcdtpkllleyiterlvqphynetlalsfskgrtlqnwkrvniivpqdpq 64
 QY 388 ERERLLSTTRGLEEQILTFLRLPKEAYLPCIIYKLLASQKTQLATTASISFSLSHQEAL 447
 Db 65 ererllsttrgleeqiltflrlpkeaylpciiyklusqktqlattaisfslshqeal 124
 QY 448 DLLFQAAKLPGEPIIRAYADLAIYNLTkdPEKKRSLHDYAKKLIQETLLFVDTENQRPH 507
 Db 125 dllfqaaklpgepiirayadlaiynltkdpekkrsldhyakkliqetllfvdtenqrph 184
 QY 508 SMPYLRYQVTPESRTKLMLDILETLATSKSSEDIRLLIQLMTEGDAKNFPVLAGLLIKIV 567
 Db 185 smpylryqvtpesrtklmldiletlatksessedirllliqlmtegdaknfpvlagllikiv 244
 QY 568 E 568
 Db 245 e 245